Molecular basis and functional characterization of human 3-methylcrotonyl-CoA carboxylase deficiency by Dantas, Maria Fernanda
 Molecular basis and functional characterization of human  
3-methylcrotonyl-CoA carboxylase deficiency 
 
 
 
 
Inauguraldissertation 
 
 
 
zur 
Erlangung der Würde eines Doktors der Philosophie  
vorgelegt der 
Philosophisch-Naturwissenschaftlichen Fakultät der 
Universität Basel 
 
 
 
Von 
Maria Fernanda Dantas 
Brazil 
 
 
 
 
 
 
Basel, 2009 
 
 
 2 
 
Genehmigt von der Philosophisch-Naturwissenschaftlichen Facultät 
auf Antrag von 
Prof. Urs A. Meyer, PD MD Dr. Matthias Baumgartner und Prof. Bendicht Wermuth  
 
 
Basel, den 04 April 2006 
 
Prof. Dr. H-J Wirz 
Dekan der Philosophisch- 
Naturwissenschaftlichen Fakultät 
             
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 3 
Acknowledgements 
 
First I would like to thank PD Dr. Matthias Baumgartner for giving me the opportunity 
to carry out my PhD thesis in his group at University Children’s Hospital in Basel and in 
Zürich. I felt at any time generously supported and beyond the scientific attendance he 
dedicated to my work I enjoyed his inspiring attitude, which contributed very much to the 
good time I had during my thesis years. 
I would like to address my special gratitude to Prof. Dr. Urs A. Meyer for his academical 
support and his valuable scientific interest in my thesis. 
I am grateful to Prof. Dr. Brian Fowler, Dr. Terttu Suormala, Dr. Cecilia Giunta and Dr. 
Patricie Paesold-Burda for the time they dedicated to my work. I appreciated the 
discussions and their expertise helped me very much to perform the experiments and to 
write the manuscript. 
At this point I would like to address my special thank to Dr. David Coelho, Rosmarie 
Meister, Mira Günther, Marianne Zaugg, Marianne Bill, Friedel Wenzel, Nemya Bosch, 
Carole Egenter, Renate Siegenthaler, Eliane Arnold and Angelika Schwarze for the warm 
working atmosphere and their kind support in times of need. Without their aid, this thesis 
would never have attained the present form. I gratefully thank Dr. Karl Heinimann to open 
his laboratory and to give me the opportunity to work closely to his group.  
Very warm thanks go to my parents who first gave me tools and to Bruno and Elena for 
their warmhearted patience and love. Thank you to be always beside me. 
 
 
 
 4 
Contents 
 
List of Abbreviations......................................................................................................6 
Single and 3-letter codes for amino acids .......................................................................7 
Abstract .........................................................................................................................8 
1. Introduction..............................................................................................................10 
1.1.  Biotin ...................................................................................................................10 
1.2. Biotin-dependent carboxylases ..............................................................................12 
1.2.1. Acetyl-CoA carboxylase (ACC) .........................................................................14 
1.2.2. Pyruvate carboxylase (PC)..................................................................................15 
1.2.3. Propionyl-CoA carboxylase (PCC) .....................................................................15 
1.2.4. 3-Methylcrotonyl-CoA carboxylase (MCC)........................................................17 
1.3. 3-Methylcrotonyl-CoA carboxylase deficiency......................................................19 
1.4. Newborn screening by tandem mass spectrometry (TMS) .....................................21 
2. Objectives ................................................................................................................24 
2.1. Outline of the thesis...............................................................................................25 
3. Molecular characterization of MCC-deficient patients by identification of new MCCA   
and MCCB mutant alleles. ...........................................................................................26 
3.1. 3-Methylcrotonyl-CoA carboxylase deficiency: mutation analysis in 28 probands, 9   
symptomatic and 19 detected by newborn screening.....................................................27 
3.2. Consanguineous 3-methylcrotonyl-CoA carboxylase deficiency: early-onset   
necrotizing encephalopathy with lethal outcome...........................................................44 
3.3. Isolated biotin resistant 3-methylcrotonyl-coenzyme A carboxylase deficiency in a  
child with metabolic stroke...........................................................................................50 
 5 
4. Consequences of MCCA and MCCB missense mutations on MCC activity, and  
analysis of steady-state levels of mutant MCCα protein. ..............................................52 
5. Investigation of molecular defects with dominant-negative effect on MCC activity. .58 
5.1. Isolated 3-methylcrotonyl-CoA carboxylase deficiency: evidence for an allele  
specific dominant negative effect and responsiveness to biotin therapy ........................60 
6. Genotype-Phenotype Correlation..............................................................................79 
7. Summary..................................................................................................................82 
7.1. Molecular characterization of MCC-deficient patients by identification of new  
MCCA and MCCB mutant alleles. ...............................................................................82 
7.2. Consequences of MCCA and MCCB missense mutations on MCC activity and  
analysis of steady-state levels of mutant MCCα  protein. .............................................83 
7.3. Investigation of molecular defects with dominant-negative effect on MCC activity  
....................................................................................................................................84 
7.4. Genotype-Phenotype Correlation...........................................................................85 
8. Outlook....................................................................................................................86 
References ...................................................................................................................87 
 
 
 
 
 
 
 
 
 
 6 
 
List of Abbreviations 
 
3-HIVA 3- hydroxyisovaleric acid 
3-MCG 3- methylcrotonylglycine  
ACC  acetyl-CoA carboxylase 
bp  base pairs 
cDNA  complementary DNA  
CG  complementation group 
CG1 and CG2, complementation group 1 and 2, respectively 
kDa  kilo daltons  
MCC  3-methylcrotonyl-CoA carboxylase 
MCCA  gene encoding the MCCα subunit 
MCCB  gene encoding the MCCβ subunit 
MCD  multiple carboxylase deficiency 
mRNA messenger RNA 
NMD  nonsense mediated mRNA decay 
ORF  open reading frame 
PA  propionic acidemia  
PC  pyruvate carboxylase 
PCC  propionyl-CoA carboxylase 
PCCA  gene encoding the PCCα subunit 
PCCB  gene encoding the PCCβ subunit 
PCR  polymerase chain reaction 
PTC  premature termination codon 
RT-PCR reverse transcriptase PCR 
TMS  tandem mass spectrometry 
 
 
 7 
 
Single and 3-letter codes for amino acids 
  Alanine Ala A 
  Cysteine Cys C 
  Aspartic Acid Asp D 
  Glutamic Acid Glu E 
  Phenylalanine Phe F 
  Glycine Gly G 
  Histidine His H 
  Isoleucine Ile I 
  Lysine Lys K 
  Leucine Leu L 
  Methionine Met M 
  Asparagine Asn N 
  Proline Pro P 
  Glutamine Gln Q 
  Arginine Arg R 
  Serine Ser S 
  Threonine Thr T 
  Valine Val V 
  Tryptophan Trp W 
  Tyrosine Tyr Y 
 
 
 
 
 
 
 
 
 
 
 
 
 8 
 
Abstract 
3-Methylcrotonyl-CoA carboxylase (MCC) deficiency is a rare disorder of leucine 
catabolism inherited as an autosomal recessive trait. The phenotypic expression of the 
disease is highly variable, ranging from neonatal onset with severe neurological 
involvement to asymptomatic adults. Most patients, however, are asymptomatic until an 
episode of acute metabolic decompensation following intercurrent illness leads to the 
diagnosis. The metabolic phenotype of MCC deficiency includes a characteristic organic 
aciduria with greatly increased excretion of 3-hydroxyisovaleric acid and 3-
methylcrotonylglycine and elevated blood levels of 3-hydroxyisovalerylcarnitine, usually in 
combination with severe secondary carnitine deficiency due to urinary loss of carnitine 
esters. Introduction of tandem mass spectrometry (TMS) to newborn screening has revealed 
an unexpectedly high incidence of MCC deficiency and indicates that this disorder is the 
most frequent organic aciduria.  
MCC is one of the four biotin-dependent carboxylases present in humans. MCC is a 
mitochondrial enzyme composed of biotin containing α subunits and smaller β subunits, 
encoded by MCCA and MCCB, respectively. In order to understand the molecular biology 
of human MCC, including the molecular defects causing MCC deficiency and their 
functional consequences, MCC-deficient patients were studied and attempts were made to 
correlate molecular defects with the phenotypic variability in our patient population. 
In this thesis mutation analysis is described in 30 MCC-deficient probands, of whom 10 
came to attention because of clinical symptoms, 18 were asymptomatic newborns detected 
by TMS based newborn screening, and 2 were affected but asymptomatic mothers 
diagnosed by abnormal metabolites in the neonatal screening samples of their healthy 
babies. Among these 30 probands, 11 have mutations in MCCA, and 19 in MCCB. We 
identified 10 novel MCCA and 14 novel MCCB mutant alleles including missense, 
nonsense, frameshift and splice site mutations.  
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In order to confirm the functional consequences of MCCA and MCCB missense 
mutations, we used transient transfection of SV40T-transformed MCCA and MCCB 
deficient skin fibroblasts to express 1 MCCA and 3 MCCB missense alleles. The MCCB 
missense alleles expressed showed no or very low residual activity, whereas the MCCA 
missense allele had 26% residual activity of wild type, thus confirming that 3 out of 4 
missense alleles expressed have a deleterious effect on enzyme activity. The apparent 
severity of MCC mutations contrasts with the variety of clinical phenotypes found in MCC-
deficient patients. Our data demonstrate no clear correlation between genotype and 
phenotype suggesting that factors other than the genotype at the MCC loci have a major 
influence on the phenotype of MCC deficiency. 
To analyse the MCC polypeptides under steady-state condition in fibroblasts of MCCA 
deficient patients, we carried out Western blot analysis. Our results demonstrate that the 
MCCα protein was absent in 5 patients homozygous or compound heterozygous for 
nonsense or frameshift mutations that are expected to result in a truncated protein. The 
MCCα protein was also absent in 2 further compound heterozygous patients in whom only 
one missense allele could be identified in the RT-PCR products. The second allele could 
not be detected because presumably this mutant allele is unstable and degraded by the 
mechanisms of nonsense-mediated mRNA decay. In contrast, Western blot analysis of the 
MCCα protein was normal in amount and size in 4 patients carrying MCCA-p.R385S. This 
is in agreement with previous studies, which show that the protein product of this allele is 
stable. 
 Finally, we provide evidence that the missense mutation MCCA-p.R385S has a 
dominant negative effect on the activity of wild type. Biotin can partially reverse this 
negative effect and result in biotin responsiveness in vivo. This is the first example of biotin 
responsiveness for an isolated partial deficiency of any of the biotin-dependent 
carboxylases, suggesting that therapeutic trials with biotin in patients carrying this mutant 
allele are warranted. 
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1. Introduction 
1.1.  Biotin 
Biotin was first isolated as a yeast growth factor from egg yolk in 1936 by Kögl and 
Tönnis (Kögl and Tönnis, 1936). Its structure was determined soon after by du Vigneaud 
and colleagues (du Vigneaud et al. 1942), and it was first synthesised two years later by 
Harris and collaborators (Harris et al. 1943).  
Biotin (C10H16O3N2S) is a heterocyclic ring that is attached to an aliphatic side chain 
terminating in a carboxyl group. Of the eight different isomers, only d-biotin exhibits 
coenzyme activity and is found in nature. Biotin is widely distributed in plants and animal 
tissues and is readily synthesized by a variety of microorganisms. This essential 
micronutrient for mammals is a member of the B vitamin complex and is present in all 
natural foodstuffs. Some of the rich sources of biotin are egg yolk, liver, milk and soya. 
Biotin deficiency is extremely rare and occurs only in special dietary situations, such as 
excessive intake of raw eggs. Raw egg white contains the glycoprotein avidin that binds 
very tightly biotin, preventing its absorption (Eakin et al. 1940). Biotin deficiency in 
animals was demonstrated in rats fed raw egg white (Bateman 1916). They developed a 
syndrome called “egg white injury”, that consisted of dermatitis, hair loss and 
neuromuscular dysfunction which could be cured by biotin  (Parsons et al. 1937). Therefore 
biotin was called vitamin H (H stands for Haut, the German word for skin).  
The steps involved in biotin metabolism in mammals are depicted in figure 1.1. Biotin 
serves as a prosthetic group of four important carboxylases, 3-methylcrotonyl-CoA 
carboxylase (MCC; EC 6.4.1.4), propionyl-CoA carboxylase (PCC; EC 6.4.1.3), pyruvate 
carboxylase (PC; EC 6.4.1.1) and acetyl-CoA carboxylase (ACC; EC 6.4.1.2), which are 
involved in central processes of protein, carbohydrate, and fatty acid metabolism (Samols et 
al. 1988, Wolf 2001). Biotin is attached to the ∈-amino group of a specific lysine in the 
inactive apocarboxylases, thus forming active holoenzymes. This holoenzyme formation is 
catalysed by holocarboxylase synthetase (HCS; EC 6.3.4.10) (Wolf and Feldman 1982). 
 11 
After proteolytic degradation of holocarboxylases from either endogenous or dietary 
sources biotin remains bound to lysine (biocytin) or to short biotinyl-peptides. Biotin is 
released from these compounds by biotinidase (EC 3.5.1.12) thus enabling recycling of 
biotin, i.e. its use for the synthesis of new holocarboxylases (Wolf and Feldman 1982). 
Figure 1.1: The biotin cycle. MCC, 3-methylcrotonyl-CoA carboxylase; PCC, propionyl-CoA 
carboxylase; PC, pyruvate carboxylase; ACC, acetyl-CoA carboxylase. Modified from Wolf et al. 
1986. 
 
Deficiency of either HCS or biotinidase causes multiple carboxylase deficiency (MCD) 
leading to typical organic aciduria and severe life threatening illness. In biotinidase 
deficiency MCD results from progressive development of biotin deficiency due to inability 
to liberate and recycle biotin, which is lost in urine as biocytin. Common symptoms in 
patients with MCD are metabolic acidosis, hypotonia, seizures, ataxia, and cutaneous 
symptoms such as skin rash and hair loss and the occurrence of episodes of massive ketosis 
which may lead, when not treated, to dehydration, coma and death (Baumgartner and 
Suormala 1997). The measurement of carboxylase activities in lymphocytes provides direct 
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evidence of MCD. These activities are low in HCS deficiency but may be normal in 
biotinidase deficiency, depending on the degree of biotin deficiency. The two disorders can 
be easily distinguished by assay of biotinidase activity in serum calorimetrically, an assay 
that is today included in many neonatal screening programs worldwide (Baumgartner and 
Suormala 1997). Most HCS and all biotinidase deficient patients respond dramatically to 
pharmacological doses of biotin. 
1.2. Biotin-dependent carboxylases 
The four biotin-dependent carboxylases are enzymes with diverse roles in intermediary 
metabolism but common structural features. Members of this family have three structurally 
conserved functional domains: (i) the biotin carboxyl carrier domain, which carries the 
biotin prosthetic group; (ii) the biotin carboxylation domain, which catalyses the 
carboxylation of biotin; (iii) and the carboxyltransferase domain, which catalyses the 
transfer of a carboxyl group from carboxybiotin to the organic substrate specific for each 
carboxylase (Samols et al. 1988, Jitrapakdee and Wallace 2003). 
 In this group of enzymes biotin serves as a covalently bound “CO2” carrier for reactions 
in which a carboxyl group is bound into an acceptor (Wolf and Feldman 1982). The 
reaction processes in two steps. The first partial reaction involves the formation of the 
carboxybiotinyl enzyme using bicarbonate as the carboxyl donor (the biotin carboxylase 
reaction; equation A). In the second partial reaction, the carboxyl group is transferred from 
the enzyme-CO2 complex to a specific acceptor substrate (the carboxyl-transferase reaction; 
equation B) (Wolf and Feldman 1982) 
 
          Mg2+ 
(A) Enzyme-biotin + ATP + HCO3-                         Enzyme-biotin-CO2 + ADP + Pi 
 
(B) Enzyme-biotin-CO2 + acceptor               Enzyme-biotin + acceptor-CO2 
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                         Mg2+ 
Net: HCO3-  + ATP + acceptor              acceptor-CO2 +ADP + Pi 
 
  
 
MCC, PCC and PC are localized to the mitochondria, while ACC is cytosolic (Samols et 
al. 1988, Wolf 2001). The genes for all human carboxylases have been cloned and 
characterized (Abu-Elheiga et al. 1995, Baumgartner et al. 2001, Freytag and Collier 1984, 
Lamhonwah et al. 1986).  
Isolated deficiencies of each of the four biotin-dependent carboxylases have been 
described in man (Figure 1.2). All isolated deficiencies are characterized by an abnormal, 
often typical profile of organic acids in urine, which is caused by the accumulation of one 
or more intermediate compounds and is the clue to diagnosis. The deficiencies of MCC, 
PCC and PC are inherited as autosomal recessive traits. The diagnosis is confirmed by 
direct enzyme assay in lymphocytes or cultured fibroblasts. In contrast to MCD, none of the 
isolated carboxylase deficiencies have so far been shown to respond to biotin therapy.  
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Figure 1.2:  The carboxylase deficiencies. Black bars indicate sites of enzyme defects. Full and 
dotted lines indicate that one or several enzymes are involved, respectively. Pyr, pyruvate; lac, 
lactate; OAA, oxaloacetate; MCC, 3-methylcrotonyl-CoA carboxylase; PCC, propionyl-CoA 
carboxylase; PC, pyruvate carboxylase; ACC, acetyl-CoA carboxylase. Modified from Baumgartner 
and Suormala, in press. 
 
1.2.1. Acetyl-CoA carboxylase (ACC) 
ACC is a cytosolic allosteric enzyme catalysing the first, rate limiting step of fatty acid 
synthesis by converting acetyl-CoA to malonyl-CoA (Wolf 2001). ACC is activated by 
citrate or isocitrate, which induce polymerisation to its active form.  
The human ACC gene maps to chromosome 17q12, and the cDNA sequence has an 
open reading frame of 7038 bp that encodes 2346 amino acids. Northern blot analysis 
revealed an ACC mRNA of 10 kb with high expression in liver and skeletal muscle (Abu-
Elheiga et al. 1995). 
A single case of isolated ACC deficiency has been reported in the literature (Blom 
1981). This patient was a newborn girl with severe brain damage and persistent myopathy. 
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ACC activity in liver biopsy and cultured skin fibroblasts was severely reduced while the 
activity of PCC was normal, confirming isolated ACC deficiency.  
1.2.2. Pyruvate carboxylase (PC) 
PC is an intra mitochondrial allosteric enzyme converting pyruvate to oxalacetate, thus 
having an important anaplerotic function in providing this intermediate to the citric acid 
cycle. In addition, it catalyses the first reaction of the gluconeogenetic pathway (Robinson 
2001). The active enzyme molecule is formed of four tightly bound identical subunits. Each 
subunit has one molecule of covalently bound biotin and contains a binding site for acetyl 
CoA, its allosteric activator (Barden et al. 1975, Scrutton and White 1974).      
The human PC gene has been mapped to the long arm of chromosome 11 at 11q13, and 
has 19 exons spanning over 16 kb of genomic DNA (Freytag and Collier 1984, Lim et al. 
1988).  
PC deficiency (MIM 266150) can manifest in two main forms (Robinson 2001). In the 
more severe form, patients present shortly after birth with severe lactic academia associated 
with hyperammonemia, citrullinemia, and hyperlysinemia; the patients of this group rarely 
survive to more than three months of age. No PC activity can be detected in fibroblasts. In 
the less severe form, patients present in the first months of life with mild to moderate lactic 
acidemia and delayed development. Some residual PC activity can be detected in cultured 
fibroblasts of these patients. Furthermore, a single case with mild symptoms consisting of 
episodic acidosis with no psychomotor retardation has been described (Van Coster et al. 
1991).      
1.2.3. Propionyl-CoA carboxylase (PCC) 
In the mitochondrial matrix PCC catalyses the carboxylation of propionyl-CoA to D-
methylmalonyl-CoA in the catabolic pathway of the amino acids isoleucine, valine, 
threonine, and methionine, as well as of odd-chain fatty acids and the side chain of 
cholesterol (Fenton et al. 2001; Figure 1.2). PCC is composed of two nonidentical α− and 
 16 
β−subunits, encoded by PCCA and PCCB, respectively  . Τhe active enzyme is thought to 
be a dodecamer comprised of six heterodimers (α6β6) (Fenton et al. 2001). The cDNA 
predicts a human α-subunit of 2106 bp encoding a 702 amino acid polypeptide of 72 kDa, 
which contains the biotin binding site. The β-subunit cDNA contains 1617 bp encoding a 
539 amino acid polypeptide of 56 kDa (Lamhonwah et al. 1986). The human PCCA and 
PCCB structural genes have been mapped to chromosome 13q32 and chromosome 3q13.3–
q22, respectively (Lamhonwah et al. 1986).  
Isolated deficiency of PCC causes propionic acidemia (PA; MIM 606054), one of the 
most frequent inborn errors of organic acid metabolism. Most of the affected individuals 
present within the first days or weeks of life with vomiting, hypotonia, hyperammonemia, 
developmental delay and in some cases early death (Wolf et al. 1981). Some patients have 
presented later either with acute encephalopathy and episodic ketoacidosis or with 
developmental retardation apparently uncomplicated by attacks of ketosis or acidosis 
(Mahoney et al. 1971, Surtees et al. 1992). A few patients with almost complete deficiency 
of PCC activity in fibroblasts remain asymptomatic, and have been identified only during 
family studies (Wolf et al. 1979, Kuhara et al. 1988). Although PA can be treated by 
protein restriction and supplementation of carnitine, the outcome for patients is usually 
poor, mental retardation and movement disorders occurring frequently in survivors.  
Because the enzyme is composed of two independently encoded subunits the causative 
mutations will necessarily occur in one of the two genes. In a mutation update and review 
of the functional and structural effects of different mutant alleles in PA, Desviat and 
colleagues reported in 2004 41 mutations in PCCA and 54 in PCCB, most of them being 
single base pair substitutions causing an amino acid change. How these mutations affect the 
enzyme has not been well established and how each mutation accounts for the patients’ 
phenotype is difficult to determine because most of the PA patients are compound 
heterozygotes.  
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1.2.4. 3-Methylcrotonyl-CoA carboxylase (MCC) 
MCC catalyses the fourth step of the leucine catabolic pathway by carboxylating 3-
methylcrotonyl-CoA at carbon-4 to form 3-methylglutaconyl-CoA (Figure 1.3) 
(Sweetmann and Williams 2001). In contrast to human MCC, bovine MCC is involved also 
in the catabolism of isovalerate, and has been implicated as a component enzyme of the 
mevalonate shunt (Lau et al. 1980).   
Isolation and purification of MCC from mitochondrial bovine kidney shows an enzyme 
with an approximate size of 835 kDa that appears to be comprised of six heterodimers 
(α6β6) (Lau et al. 1980). Similar to PCC, MCC has a larger α−subunit, which covalently 
binds biotin and contains the biotin carboxylation domains and a smaller β−subunit, which 
contains the carboxyltransferase domain (Sweetman and Williams 2001). MCC is 
predominantly localized to the inner membrane of mitochondria and is highly expressed in 
kidney and liver (Sweetmann and Williams 2001). 
Using homology probing and the known cDNAs from Arabidopsis thaliana and other 
plants (Mckean et al. 2000, Weaver et al. 1995), three independent groups have cloned 
human and murine cDNAs encoding both subunits of MCC, confirmed their identity by 
biochemical and molecular genetic studies and identified mutations in MCC-deficient 
patients (Baumgartner et al. 2001, Gallardo et al. 2001, Holzinger et al. 2001). 
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Figure 1.3. The MCC-catalysed reaction and its position in the leucine catabolic pathway. Each 
arrow represents a enzymatic step. The dashed arrow indicates the metabolites that accumulate due 
to deficiency of MCC. Modified from Sweetman and Williams 2001 
 
The cDNAs predict a human MCCα of 725 amino acids with a calculated molecular 
mass of 80 kDa, a mouse MCCα of 717 amino acids with a calculated molecular mass of 
79 kDa, and human and mouse MCCβ of 563 amino acids with a calculated molecular mass 
of 61 kDa. Human MCCα has 84% and 45% identity to MCCα of mouse and A. thaliana, 
respectively. Human MCCβ has 89% and 60% identity to MCCβ of mouse and A. thaliana, 
respectively (Baumgartner et al. 2001). The human MCCA and MCCB structural genes 
have been mapped to chromosome 3q25-q27 and 5q12-q13.1 and have 19 and 17 exons, 
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respectively (Baumgartner et al. 2001, Gallardo et al. 2001, Holzinger et al. 2001). At the 
beginning of this study, 9 MCCA and 13 MCCB functionally significant mutant alleles had 
been reported including missense, nonsense, frameshift and splice site mutations 
(Baumgartner et al. 2001, Desviat et al. 2003, Gallardo et al. 2001, Holzinger et al. 2001). 
1.3. 3-Methylcrotonyl-CoA carboxylase deficiency 
Isolated biotin-resistant MCC deficiency (MIM 210200) is an autosomal recessive 
disorder caused by defects in either the α− or β-subunit of MCC. The diagnosis is 
confirmed by enzyme assays in lymphocytes and/or cultured skin fibroblasts, which show 
severely reduced, or absent MCC, but normal PCC and PC activity (Baumgartner 1990). 
To date, most patients with confirmed isolated biotin-resistant MCC deficiency have a 
characteristic organic aciduria with elevated excretion of 3-hydroxyisovaleric acid (3-
HIVA) and 3-methylcrotonylglycine (3-MCG). In addition, acyl-CoA derivatives 
accumulate and are trans-esterified to acylcarnitine esters. The major abnormal metabolite, 
3-hydroxyisovalerylcarnitine, is found in blood and urine (Sweetman and Williams 2001) 
and can be easily detected by tandem mass spectrometry (TMS) in dried blood spots. 
Owing to the enzyme block, 3-methylcrotonyl-CoA accumulates within the mitochondria, 
and, by an alternative mechanism, 3-MCG and 3-HIVA are formed. Whereas 3-MCG can 
directly cross mitochondrial membranes, 3-HIVA can do this only after deacylation or 
conjugation with carnitine. After reaching the cytosol, all these compounds are readily 
excreted in the urine, leading to secondary carnitine deficiency (Sweetman and Williams 
2001).  
In 1970 Eldjarn and colleagues identified a new inborn error in the leucine catabolic 
pathway that was different from maple syrup urine disease and isovaleric acidaemia. They 
reported on a 41/2–month-old girl of consanguineous parents that presented at 2 weeks of 
age with feeding difficulties. Progressively the signs of retarded motor development, 
muscular hypotonia and atrophy appeared. Her urine had the odour of cat’s urine and she 
excreted large amounts of two abnormal metabolites, 3-HIVA and 3-MCG. The 
characteristic odour and the 3-HIVA level decreased significantly when she was put on a 
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low-leucine diet (150 mg leucine/kg body weight/day). However, this diet did not improve 
the child’s symptoms, even after extra supply of biotin (0.25 mg/day), and she died at the 
age of nine months. No enzymatic assay was performed. Today it is still not known if this 
patient had isolated MCC deficiency or a severe form of MCD. 
Thereafter several patients with MCC deficiency were reported. However, most of these 
patients were subsequently found to have MCD  (Bartlett et al. 1980, Gompertz and 
Draffan 1971, Gompertz et al. 1973). 
The first well characterized patients with isolated biotin-resistant MCC deficiency were 
2 siblings from Vietnam, a boy and a girl, reported by Beemer et al. in 1982. When the boy 
was almost 5 years old he arrived in the Netherlands and four weeks later started to vomit 
and was admitted to the hospital in subcoma. Until this time there were no physical 
abnormalities apart from severe dental caries. Laboratory data showed elevated urinary 
concentrations of 3-HIVA and 3-MCG. MCC deficiency was confirmed in both patients by 
direct enzyme assay in leukocytes and cultured fibroblasts showing deficient MCC activity 
while activities of the 3 other biotin-dependent carboxylases were found to be normal. 
MCC activity in his young sister was performed and MCC deficiency diagnosis confirmed. 
The authors speculated that the change from a low protein diet in Vietnam to a high protein 
diet in the Netherlands might have contributed to the metabolic decompensation in the first 
patient. Both patients did not respond to biotin treatment and developed normally on a 
protein-restricted diet (Beemer et al., 1982).  
Most patients with isolated MCC deficiency develop normally until they present with an 
episode of metabolic decompensation frequently following intercurrent illness, usually 
between the age of 1 and 3 years. Symptoms include hypotonia, hypoglycaemia, 
hyperammonemia, ketonuria, seizures and Reye-like syndrome (Bartlett et al. 1984, 
Layward et al. 1989, Pearson et al. 1995). They usually respond to intravenous fluids and 
cessation of protein feeding, and are asymptomatic between acute episodes. Some affected 
subjects have been placed on a diet modestly restricted in leucine with oral L-carnitine 
supplements, but the efficacy of this approach is unproven. 
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In some cases however, the above mentioned treatment did not improve the patient’s 
condition, and 4 patients had a fatal outcome. All of these patients were the product of a 
consanguineous union and could have an additional genetic disorder that was not detected. 
(Bannwart et al. 1992, Baykal et al. 2005, Wiesmann et al. 1998).  
A few patients showed a severe form presenting in the early neonatal period with failure 
to thrive, global developmental delay and neurological complications (Kremer et al, 2002, 
Lehnert et al. 1996, Murayama et al. 1997, Yap et al. 1998).  
Some families with several affected siblings and also affected parents have been 
reported and showed a high phenotypic variability even within the same family. Jurecki and 
Packman in 1992 reported a family with four affected siblings, two of whom were 
asymptomatic, one of whom had mild metabolic abnormalities but normal development, 
while the last one had severe symptoms and died at the age of 2 years and 2 months. In 
another family with three affected siblings only one had mild developmental delay at the 
age of 1 year while the other two were asymptomatic at the age of 6 years and 3 months 
(Mourmans et al. 1995). Visser and collaborators reported in 2000 a MCC-deficient patient 
with congestive heart failure and normal psychomotor development. Evaluation of family 
members revealed an affected brother with no cardiac abnormalities but delayed 
psychomotor development, whereas the father was also affected but asymptomatic.        
Finally, some affected but virtually asymptomatic mothers were diagnosed only after 
detection of abnormal metabolites in the neonatal screening samples of their healthy babies 
(Dantas et al. 2005, Gibson et al. 1998, this thesis).  
1.4. Newborn screening by tandem mass spectrometry (TMS)  
In industrialised countries, genetic disorders have become a significant factor with 
regard to handicap and mortality, and the development of optimised screening strategies to 
detect a maximal number of treatable metabolic disorders is a major challenge for 
preventive medicine. In some countries genetic disorders occur with an incidence of 1:1500 
live births due to high rates of consanguineous parents (Joshi et al. 2002). Among other 
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factors, early diagnosis and treatment are crucial determinants for outcome in many genetic 
metabolic diseases.  
In Switzerland newborn screening using dried blood spots on filter paper (Guthrie card) 
was introduced in the 1960’s. Until 2005 this screening, as in many countries, was based on 
a one method-one disorder principle and included six different disorders.  
TMS provides a one method-many disorders principle which potentially allows 
simultaneous screening for over 30 rare inborn errors of metabolism (Röschinger et al. 
2003). TMS has advanced to the forefront of newborn screening technology by eliminating 
several technical problems associated with previous screening technology, such as high 
false positive rates and the expense of individual tests (Chace et al. 1999, Chace et al. 2001,  
Rashed et al. 1995). The cost of TMS based newborn screening is low given the speed of 
automated systems that are able to analyse multiple metabolites in up to 500 samples per 
instrument in a single day. TMS based newborn screening can be used to detect disorders of 
amino acid, organic acid, and fatty acid metabolism by measuring amino acids and 
acylcarnitines. Most of the disorders have a birth incidence of less than 1:50’000 
(Röschinger et al. 2003) 
Among the disorders that may be diagnosed, some cause severe illness or death within 
the first few days of life, and newborn screening may serve only to suggest a diagnosis that 
might otherwise have been missed. However, most of the disorders are treatable if they are 
diagnosed early.  
Newborn screening using TMS is currently being utilized in at least seven states in the 
United States and in other countries including Australia and Germany, and introduction of 
this technology is being considered nationally as a way to improve the presymptomatic 
detection of inborn errors of metabolism (Aurey-Blais et al. 2003, Hoffmann et al. 2004, 
Koeberl et al. 2003, Schulze et al. 2003, Wilcken et al. 2000, Zytkovicz et al. 2001).  
Three recent studies of TMS based newborn screening programs in North Carolina, 
Germany and Australia showed a high incidence of sustained elevation of 3-
hydroxyisovalerylcarnitine (C5OH), a marker for MCC deficiency (Koeberl et al. 2003, 
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Schulze et al. 2003, Wilcken et al. 2003). In these studies the estimated incidence of MCC 
deficiency was about 1 in 50’000 infants. Although it is possible that some of these infants 
may never develop clinically significant disease, carnitine deficiency was detected in 4 out 
of 8 infants upon initial investigation (Koeberl et al. 2003). Based on these studies, MCC 
deficiency appears to be the most frequent organic aciduria detected in newborn screening 
programs using TMS. 
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2. Objectives  
Isolated, biotin-resistant 3-methylcrotonyl-CoA carboxylase (MCC) deficiency is an 
autosomal recessive disorder of leucine catabolism that appears to be the most frequent 
organic aciduria detected in tandem mass spectrometry based neonatal screening programs 
with a frequency of about 1:50’000 (Koeberl et al. 2003; Schulze et al.2003; Wilcken et al. 
2003). The phenotype is variable, ranging from neonatal onset with severe neurological 
involvement to asymptomatic adults. MCC is a heteromeric mitochondrial enzyme 
composed of biotin containing α subunits and smaller β subunits, encoded by MCCA and 
MCCB, respectively.  
The specific aims of this thesis are: 
a. Identification of MCCA and MCCB mutations 
b. Determination of the consequences of these mutations on MCC function 
c. Analysis of steady-state levels of normal and abnormal MCCα protein 
d. Identification and investigation molecular defects with dominant negative 
effects on MCC activity 
e. To increase the understanding of the variables influencing the phenotypic 
consequences of MCC deficiency 
 Finally, knowledge obtained from studies on MCC will serve as an example for other 
biotin-dependent enzymes and their disorders. 
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2.1. Outline of the thesis 
The material of the experimental section is composed of the following manuscripts, 
which have been published: 
a. Dantas MF, Suormala T, Randolph A, Coelho D, Fowler B, Valle D, Baumgartner 
MR. 3-Methylcrotonyl-CoA carboxylase deficiency: Mutation analysis in 28 probands, 9 
symptomatic and 19 detected by newborn screening. Hum. Mutat. 26(2):164 2005 
b. Baykal T, Humer Gokcay G, Ince Z, Dantas MF, Fowler B, Baumgartner MR, Demir 
F, Can G, Demirkol M. Consanguineous 3-methylcrotonyl-CoA carboxylase deficiency: 
early-onset necrotizing encephalopathy with lethal outcome J. Inherit. Metab. Dis. 
28(2):229-33 2005 
c. Pinto LLC, Zen P, Rosa R, Paskulin G, Perla A, Barea L, Baumgartner MR, Dantas 
MF, Fowler B, Giugliani R, Vargas CR, Wajner M, Graziadio C. Isolated Biotin Resistant 
3-Methylcrotonyl-Coenzyme A carboxylase deficiency in a child with metabolic stroke. J. 
Inherit. Metab. Dis. in press 
d. Baumgartner MR, Dantas MF, Suormala T, Almashanu S, Giunta C, Friebel D, 
Gebhardt B, Fowler B, Hoffmann GF, Baumgartner ER, Valle D. Isolated 3-
methylcrotonyl-CoA carboxylase deficiency: evidence for an allele-specific dominant 
negative effect and responsiveness to biotin therapy. Am. J. Hum. Genet. 75:790-800 2004 
These manuscripts are presented in the chapters 3 (a, b and c) and 5 (d). 
Chapter 4 is focused on the consequences of MCCA and MCCB missense mutations on 
MCC activity and analysis of steady-state levels of mutant MCCα protein. 
In chapter 6 the question of whether there is any correlation between the molecular 
defects and the phenotypic variation in our patient population is evaluated.  
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3. Molecular characterization of MCC-deficient patients by identification of 
new MCCA and MCCB mutant alleles. 
The metabolic unit at the Children’s Hospital of Basel has a longstanding interest in 
inborn errors of biotin metabolism. They are one of the few reference laboratories 
worldwide providing enzyme activity measurement for the carboxylases. Consequently, 
they have a large, well-characterized collection of fibroblast cell lines from patients with 
isolated MCC deficiency, and includes 75 patients from 70 families from several different 
nationalities and ethnic backgrounds. From each family an individual proband was included 
in this study. 32 of these probands presented with an acute metabolic decompensation and 
were sent to Basel for enzymatic confirmation of suspected MCC deficiency. Case reports 
with biochemical data and clinical symptoms of many of these patients have been reported 
earlier (Bannwart et al.. 1992, Baumgartner et al.. 2004, Baykal et al.. 2005, Beemer et al.. 
1982, Gibson et al.. 1998, Gitzelmann et al.. 1997, Jurecki and Packmann 1992, Kremer et 
al.. 2002, Lehnert et al.. 1996, Mourmans et al.. 1995, Pinto et al.. in press, Stehen et al.. 
1999, Tsai et al.. 1989, Visser et al.. 2000, Wiesmann et al.. 1998). The remaining 38 
MCC-deficient probands were asymptomatic newborns detected by TMS based newborn 
screening, including 4 mothers identified only by detection of abnormal metabolites in the 
neonatal screening samples of their healthy babies. MCC deficiency seems to be the most 
frequent organic aciduria detected using TMS based newborn screening. The incidence of 
MCC deficiency is estimated to be about 1:50’000 live births in North America, Europe 
and Australia (Koeberl et al.. 2003, Schulze et al.. 2003, Wilcken et al.. 2003). 
MCC activity in fibroblasts of these patients was usually less than 2% of he median 
control value, although a few patients had activities between 2.5% and 17.6%. No 
correlation between the level of residual activity and clinical phenotype was observed.  
This chapter reports mutation analysis, clinical and biochemical data from 28 of these 
MCC-deficient patients (Baykal et al.. 2005, Dantas et al.. 2005, Pinto et al.. in press).  
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3.1. 3-Methylcrotonyl-CoA carboxylase deficiency: mutation analysis in 28 
probands, 9 symptomatic and 19 detected by newborn screening 
Dantas MF, Suormala T, Randolph A, Coelho D, Fowler B, Valle D, Baumgartner MR. Hum. Mutat. 
26(2):164 2005 
 
Abstract 
Isolated 3-methylcrotonyl-CoA carboxylase (MCC) deficiency is an autosomal recessive 
disorder that appears to be the most frequent organic aciduria detected in tandem mass 
spectrometry (TMS)-based neonatal screening programs. The phenotype is variable, 
ranging from neonatal onset with severe neurological involvement to asymptomatic adults. 
MCC is a heteromeric mitochondrial enzyme composed of biotin containing α subunits and 
smaller β subunits, encoded by MCCA and MCCB, respectively. We report mutation 
analysis in 28 MCC-deficient probands, 19 of whom were asymptomatic newborns detected 
by TMS newborn screening, and nine presented with clinical symptoms. Ten have 
mutations in MCCA, and 18 in MCCB. We identified 10 novel MCCA and 14 novel MCCB 
mutant alleles  including missense, nonsense, frameshift and splice site mutations, and 
show that three of the missense mutations result in severely decreased MCC activity when 
expressed in MCC-deficient cell lines. Our data demonstrate no clear correlation between 
genotype and phenotype suggesting that factors other than the genotype at the MCC loci 
have a major influence on the phenotype of MCC deficiency. 
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Introduction 
Isolated biotin-resistant 3-methylcrotonyl-CoA carboxylase (MCC, EC 6.4.1.4) 
deficiency (MIM#s: MCCA-210200 and MCCB-210210) is a rare metabolic disorder 
inherited as an autosomal recessive trait (Sweetman and Williams, 2001). MCC catalyzes 
the fourth step of leucine catabolism converting 3-methylcrotonyl-CoA to 3-
methylglutaconyl-CoA in a reversible ATP dependent reaction using bicarbonate as the 
source of the carboxyl group (Sweetman and Williams, 2001). Patients with MCC 
deficiency show elevated urinary excretion of 3-hydroxyisovalerate (3-HIVA) and 3-
methylcrotonylglycine (3-MCG), usually in combination with severe secondary carnitine 
deficiency (Sweetman and Williams, 2001). In addition, acyl-CoA derivatives accumulate 
and are trans-esterified to acylcarnitine esters with 3-hydroxyisovalerylcarnitine 
characteristically present in blood and urine (Sweetman and Williams, 2001). The clinical 
presentation is extremely variable ranging from severe neurological abnormalities and 
death in infancy to asymptomatic adults detected in family studies or in mothers due to 
positive newborn screening findings in their unaffected babies (Bannwart et al.. 1992; 
Baykal et al.. 2005, Gibson et al.. 1998; Koeberl et al.. 2003; Wiesmann et al.. 1998). 
MCC is one of three mitochondrial biotin-dependent carboxylases present in man; the 
others are propionyl-CoA carboxylase (PCC) and pyruvate carboxylase (Jitrapakdee and 
Wallace, 2003). The MCC enzyme is composed of nonidentical subunits, MCCα and 
MCCβ, encoded by MCCA (MCCC1; MIM# 609010) and MCCB (MCCC2; MIM# 
609014), respectively (Baumgartner et al.. 2001; Gallardo et al.. 2001; Holzinger et al.. 
2001). The native enzyme is thought to be a α6β6 heteropolymer (Hector et al.. 1980). The 
larger MCCα subunit contains the covalently bound biotin prosthetic group and the 
bicarbonate and ATP binding sites. The MCCβ subunit binds methylcrotonyl-CoA. The 
MCCA structural gene is located on chromosome 3q25-q27 and consists of 19 exons. The 
corresponding cDNA (MCCC1 GenBank: AF310972) is 2580 bp long and encodes a 
protein of 725 amino acids. The MCCB gene is located on human chromosome 5q12-q13.1 
and consists of 17 exons. The corresponding cDNA (MCCC2 GenBank: AF 310971) is 
2304 bp long and encodes a protein of 563 amino acids (Baumgartner et al.. 2001; Gallardo 
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et al.. 2001; Holzinger et al.. 2001). To date, 9 MCCA and 13 MCCB mutant alleles have 
been reported including missense, nonsense, frameshift and splice site mutations 
(Baumgartner et al.. 2001; Desviat et al.. 2003; Gallardo et al.. 2001; Holzinger et al.. 
2001). One missense allele, MCCA-p.R385S, has been shown to have a dominant negative 
effect that may lead to biochemical abnormalities and clinical symptoms in heterozygous 
individuals (Baumgartner et al.. 2004). 
Introduction of tandem mass spectrometry (TMS) to newborn screening resulted in a 
large increase in the number of inborn errors that can be detected, including several amino 
acidemias and organic acidurias. Surprisingly, using this technique, MCC deficiency 
appears to be the most frequently detected organic aciduria in North America, Europe and 
Australia, with an overall frequency of approximately 1 in 50’000 (Koeberl et al.. 2003; 
Schulze et al.. 2003; Wilcken et al.. 2003). 
Here, we report mutation analysis in 28 MCC-deficient probands, 19 of which were 
detected by TMS based newborn screening. 
Probands and Methods 
Cell lines and enzyme assays 
28 subjects in whom MCC deficiency was suspected based on either elevated 3-MCG 
and 3-HIVA excretion or elevated 3-hydroxyisovalerylcarnitine in blood were included in 
this study. From 24 probands cultured skin fibroblasts, from 4 probands (018, 019, 025, 
026) only RNA and DNA were available. Informed consent to perform enzymatic and 
molecular genetic studies was obtained from all probands or their parents. Clinical and 
biochemical data of proband 004 (Gitzelmann et al.. 1987) and proband 030 (Baykal et al.. 
in press) have been reported earlier. Mutation analysis in probands 004 and 013 has been 
previously reported (Baumgartner et al.. 2001) with only one mutant allele identified in 
each. Fibroblasts were cultured in Earl’s minimal essential medium supplemented with 10 
% fetal calf serum, L-glutamine, and antibiotics as described earlier (Suormala et al.. 2002). 
The biotin concentration of this standard medium was 6.5 nmol/L. The activities of PCC 
and MCC were assayed in fibroblast homogenates by measuring the incorporation of 14C-
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bicarbonate into acid non-volatile products with established methods (Suormala et al.. 
1985). Somatic cell complementation was used to distinguish between α- and β-subunit 
deficiency in fibroblasts as previously described (Baumgartner et al.. 2001).  
Mutation analysis by RT-PCR and genomic PCR 
Eighteen probands were grouped by complementation analysis followed by RT-PCR 
amplification and sequencing of the entire ORF (Open Reading Frame) of either MCCA or 
MCCB, as appropriate. In the remaining 10 probands RT-PCR amplification and 
sequencing of the entire MCCB ORF was first performed and, if no coding alterations were 
detected in MCCB, the entire MCCA ORF was also analyzed. 
Total RNA and genomic DNA were extracted from cultured skin fibroblasts of 24 and 
from blood of 4 probands using the QIAamp® RNeasy and DNA isolation kits (Qiagen 
AG, Basel, Switzerland), respectively. The RT-PCR reaction was performed using the 1-
Step RT-PCR kit (Qiagen AG, Basel, Switzerland) following the manufacturer’s 
instructions. First-strand MCCA and MCCB cDNA was amplified as described 
(Baumgartner et al.. 2001). PCR products were sequenced in a thermocycler and analyzed 
with an ABI Prism 3100 Avant using the dye-terminator method (Applied Biosystem, 
Rotkreuz, Switzerland) according to the manufacturer’s instructions. To confirm mutations 
identified in RT-PCR products, a genomic fragment containing the corresponding exon was 
amplified using flanking intronic primers, and the PCR product was sequenced directly. 
In cases where only one of the two alleles could be identified in the standard RT-PCR 
product, the analysis was either repeated using fibroblasts cultured in the presence of 
Emetine (100 µg/ml medium; Sigma, Buchs, Switzerland) for 10 h before harvesting the 
cells to inhibit nonsense-mediated mRNA decay (NMD) (Carter et al.. 1995), or all exons 
and flanking intronic sequences were sequenced. The sequences of all primers are available 
upon request. 
To survey a European control population for the identified missense mutations, relevant 
exons and flanking intronic sequences were amplified from genomic DNA, and the 
 31 
indicated mutations were searched for by restriction digest or, if not possible, by direct 
sequencing of the PCR product. 
Construction of wild type and mutant MCCA and MCCB expression vectors and 
transfections 
Full-length wild type MCCA (-51 to +2275) and MCCB (-99 to +1824) cDNAs were TA 
cloned into the pCR Blunt II TOPO vector (Invitrogen, Basel, Switzerland) as described 
(Baumgartner et al.. 2001). To introduce the MCCA A291V missense mutation, an 896 bp 
ACC I restriction fragment from RT-PCR-amplified cDNA of proband 025 was subcloned 
into the pMCCA-TOPO construct. The wild type and mutant MCCA and MCCB constructs 
were then transferred into the mammalian expression vector pTracer-CMV2 (Invitrogen, 
Basel, Switzerland) at the EcoR I site. This vector contains the green fluorescent protein 
(GFP) gene fused to the Zeocin resistance gene. To introduce the MCCB H190Y and 
G352R missense mutations, a 965 bp BstE II/Sfi I restriction fragment from RTPCR-
amplified cDNA of probands 018 and 019, respectively, were subcloned directly into the 
pTracer-CMV2 vector. All constructs were sequenced in both directions to validate their 
sequences. The constructs indicated above were incorporated into either immortalized 
MCCα or MCCβ deficient cell lines by electroporation as described (Baumgartner et al.. 
2001), harvested 72 hours later and assayed for MCC and PCC activity. 
Results and Discussion 
This study provides new information on the nature of mutations in the MCCA and 
MCCB genes including expression studies in some cases, and allows a comparison of 
mutations between symptomatic patients and subjects detected by newborn screening. 
 Of 28 probands studied, 9 were diagnosed because of clinical symptoms (Table 3.1.1), 
while 19 were asymptomatic newborns detected by TMS based newborn screening (Table 
3.1.2). Carboxylase activities in fibroblast homogenates from 24 probands are shown in 
Tables 3.1.1 and 3.1.2. MCC activity was below the level of detection (< 2.0 % of the  
median control value) in 18 probands (five with a defect in MCCA and 13 in MCCB). In 6 
probands (020, 031, 034, 037, 043 and 046) MCC activity varied between 2.5% and 6.3% 
 32 
of the median control value indicating the presence of residual, albeit low enzyme activity. 
The activity of PCC was within the control range in all cell lines. 
Table 3.1.1. Genotype and laboratory findings in MCC-deficient patients detected by clinical symptoms. 
Patient Affected  
Genea 
          Allele 1b                      Allele 2b 
  (Consequences)          (Consequences) 
Clinical  
Phenotypec 
Origin  
 
 
Carboxylase Activities 
(pmol/min/mg protei) 
MCC            PCC 
013 MCCA c.1263dupG 
(frameshift) 
c.1282-3A>Ge 
(splice) 
Mild Swedish 0 1049 
036 MCCA c.1527C>A 
(nonsense) 
c.1527C>A 
(nonsense) 
Severe Turkish 0.4 420 
004 MCCB c.517dupT 
(frameshift) 
c.994C>Te 
(nonsense) 
Mild Swiss 20 1153 
018 MCCB c.568C>T 
(missense) 
c.568C>T 
(missense) 
Mild Turkish - - 
019 MCCB c.1054G>A 
(splice) 
c.1054G>A 
(splice) 
Mild Turkish - - 
030 MCCB c.1574+1G>A 
(splice) 
c.1574+1G>A 
(splice) 
Severe Turkish 0 636 
032 MCCB c.127C>T 
(nonsense) 
c.127C>T 
(nonsense) 
Mild Arabian 5.0 864 
042 MCCB c.929C>G 
(missense) 
c.929C>G 
(missense) 
Mild Australian 0 665 
044 MCCB c.463C>T 
(missense) 
c.463C>T 
(missense) 
Mild Brazilian 4.0 425 
a MCCC1 (MCCA), MIM# 609010; MCCC2 (MCCB), MIM# 609014. 
b 
cDNA variation numbering based on GenBank AF310972 (MCCA) and AF310971 (MCCB), with +1 as A of  
the ATG start codon. Consensus nomenclature according to approved guidelines (http://www.hgvs.org/mutnomen/). 
c Mild: late onset, good recovery after acute attack, no or mild developmental delay; Severe: onset in infancy,  
severe neurological involviment with severe developmental delay. 
d Control values for 3-methylcrotonyl-CoA carboxylase (MCC) and propionyl-CoA carboxylase (PCC) activities in 
 fibroblasts: MCC, median value 319 pmol/min/mg protein (range 125-831); PCC, median value 740 pmol/min/mg 
protein (range 207-2150); n=73 different control cell lines. 
e Detected only after pre-incubation of cells with Emetine prior to isolation of RNA. 
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Table 3.1.2. Genotype and laboratory findings in MCC-deficient patients detected by TMS-based newborn screening. 
Patient Affected  
Genea 
                  Allele 1b                                Allele 2b 
          (Consequences)                 (Consequences) 
Origin  
 
 
Carboxylase Activitiesc 
(pmol/min/mg protei) 
MCC            PCC 
020 MCCA c.1155A>C 
(missense) 
c.559T>C 
(missense) 
Geman 15.4 812 
025 MCCA c.872C>T 
(missense) 
RNA not detectable Australian - - 
027 MCCA c.1155A>C 
(missense) 
RNA not detectable German 1.1 305 
028 MCCA c.1155A>C 
(missense) 
Exon 15 skippingd 
(intragenic deletion) 
German 1.1 317 
031 MCCA c.1155A>C 
(missense) 
c.400G>A 
(missense) 
German 12.4 519 
041 MCCA c.694C>T 
(missense) 
RNA not detectable American 0 595 
043 MCCA c.640_641delGG 
(frameshift) 
c.1930G>T 
(nonsense/skip exon 17) 
American 8.1 705 
046 MCCA c.2088dupA 
(frameshift) 
c.1526_1527delGe 
(frameshift) 
Amercian 20.0 1054 
021 MCCB c.803G>C 
(splice) 
c.803G>C 
(splice) 
Turkish 0 275 
022 MCCB c.464G>A 
(missense) 
c.464G>A 
(missense) 
Turkish 1.9 742 
023 MCCB c.469C>T 
(nonsense) 
c.469C>T 
(nonsense) 
Turkish 0 594 
024 MCCB c.295G>A 
(missense) 
c.295G>A 
(missense) 
Turkish 1.8 390 
026 MCCB c.1690T>C 
(add 3 aa at C-terminus) 
RNA not detectable Australian - - 
029 MCCB c.295G>A 
(misssense) 
c;1574+1G>Ad 
(splice) 
Turkish 0 920 
033f MCCB c.282-1G>C 
(splice) 
c.282-1G>C 
(splice) 
Turkish 4.6 520 
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Mutation analysis 
Of the 28 probands investigated, 10 (36%) had mutations in MCCA and 18 (64%) in 
MCCB (Tables 3.1.1 and 3.1.2). Thirty-one different mutant alleles and one undefined 
intragenic deletion were identified, accounting for 52 of 56 possible mutant alleles. 
Twenty-four of the identified mutant alleles are novel, seven have been previously reported 
by us and two other groups (Baumgartner et al.. 2001; Gallardo et al.. 2001; Holzinger et 
al.. 2001). Because DNA of parents was not available in most cases, analysis of family 
members to rule out the possibility of a partial or complete deletion of the corresponding 
gene could not be performed. 
Ten novel MCCA mutant alleles were identified including 4 predicted missense 
mutations (p.E134K, p.S187P, p.R232W, and p.A291V), 2 nonsense mutations (p.C509X, 
p.E644X), 1 splice site mutation (c.1682-3A>G) and 3 frameshift mutations 
(c.640_641delGG, c.1526_1527delG and c.2088dupA) (Table 3.1.3). 
Table 3.1.2. Continue 
Patient Affected  
Genea 
                  Allele 1b                                Allele 2b 
          (Consequences)                 (Consequences) 
Origin  
 
 
Carboxylase Activitiesc 
(pmol/min/mg protei) 
MCC            PCC 
034 MCCB c.845A>G 
(missense) 
c.845A>G 
(missense) 
Italian 16.2 542 
037f MCCB c.1367C>T 
(missense) 
c.1367C>T 
(missense) 
Taiwanese 9.6 1269 
039 MCCB c.517dupT 
(frameshift) 
c.1123G>T 
(missense) 
American 0.7 696 
040 MCCB c.214C>T 
(nonsense) 
c.416_427del12ins16 
(framseshift) 
Turkish 5.1 619 
aMCCC1 (MCCA), MIM# 609010; MCC2 (MCCB), MIM# 609014. 
b
cDNA variation numbering based on GenBank AF310972 (MCCA) and AF310971 (MCCB), with +1 as A of  
the ATG start codon. Consensus nomenclature according to approved guidelines (http://www.hgvs.org/mutnomen/). 
cFor control values see footnoted to Table 1.  
d
 Detected only after pre_incubation of cells with Emetine prior to isolation of RNA. 
eDetected only by sequencing all exons and flanking intronic sequences by genomic PCR. 
fAsymptomatic mother detected by elevated 3-hydroxyisovaleryl carnitine in her nonaffected newborn. 
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We assume deleterious functional consequences for the frameshift mutations 
c.640_641delGG, c.1526_1527delG and c.2088dupA, the splice site mutation c.1682-
3A>G and the nonsense mutations p.C509X and p.E644X because they result in truncated 
proteins lacking functionally important domains such as bicarbonate and/or biotin binding 
sites (Baumgartner et al.. 2001; Jitrapakdee and Wallace, 2003). The MCCA missense 
mutations p.E134K, p.S187P, p.R232W and p.A291V all change residues that lie within the 
biotin carboxylation domain and are highly conserved (Baumgartner et al.. 2001; 
Jitrapakdee and Wallace, 2003). Moreover, in our expression studies, p.A291V was 
associated with a reduction of activity to 26% of normal confirming functional significance 
(Table 3.1.5). 
Table 3.1.3 MCCA (MCCC1) mutant alleles and their consequences. 
No. of 
alleles 
detected 
Nucleotide change at 
cDNA levela  
Exon / Intron Amino acid 
change 
Consequence 
(at RNA level)  
Reference 
1 c.400G>A exon 5 p.E143K missense novel 
1 c.559T>C exon 6 p.S187P missense novel 
1 c.694C>T exon 7 p.R232W missense novel 
1 c.872C>T exon 8 p.A291V missense novel 
4 c.1155A>C exon 11 p.R385S missense Baumgartner et al. 2001 
1 c.1527C>A exon 13 p.C509X nonsense novel 
1 c.1930G>T exon 17 p.E644X nonsense 
(skip exon 17) 
novel 
1 c.640_641delGG exon 7 p.G214IfsX5 frameshift novel 
1 c.1263dupG exon 11 p.Q421AfsX10 frameshift Baumgartner et al. 2001 
1 c.1526_1527delGc exon 13 p.C509SfsX38 frameshift novel 
1 c.2088dupA exon 19 p.V697SfsX19 frameshift novel 
1 c.1682-3A>Gb intron 14 p.N561KfsX10 splice 
(frameshift / NMD) 
novel 
a cDNA variation numbering based on GenBank AF310972, with +1 as A of the ATG start codon; genomic  
reference sequence from intronic mutations is GenBank NM_020166. 
b Detected only after pre-incubation of cells with Emetine prior to isolation of RNA. 
c Detected only by sequencing all exons and flanking intronic sequences by genomic PCR. 
NMD; nonsense-mediated mRNA decay. 
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The previously described p.R385S mutant allele found here in four compound 
heterozygous MCCA-deficient subjects of German origin is of particular relevance. An 
arginine at position 385 is strictly conserved (Jitrapakdee and Wallace, 1999), and the 
corresponding residue in the biotin carboxylation domain of E.coli acetyl-CoA carboxylase 
has been shown to be part of the bicarbonate binding pocket (Sloane and Waldrop, 2004; 
Thoden et al.. 2000). Recent studies provided evidence that this missense mutation in the 
presence of the wild type allele has a dominant negative effect that may lead to biochemical 
and clinical abnormalities in heterozygous individuals (Baumgartner et al.. 2004). 
Moreover, in such subjects biotin therapy appears to counteract the dominant negative 
effect in vivo (Baumgartner et al.. 2004). We speculate that the occurrence of MCCA-
p.R385S together with other mutant alleles that have residual activity may also respond to 
biotin therapy suggesting that therapeutic trials with biotin in subjects carrying this mutant 
allele are warranted (e.g. probands 020 and 031). 
Fourteen novel mutant alleles were identified within the 18 MCCβ-deficient subjects 
including five predicted missense mutations (p.R155W, p.H190Y, p.H282R, p.A456V and 
p.V375F), one missense mutation which causes a substitution of the translational stop 
codon by adding 3 amino acids to the C-terminus of the β-subunit (p.X564QLE, Fig. 3.1.1), 
four nonsense mutations (p.R332X, p.Q157X, p.Q43X and p.R72X), three splice site 
mutations (c.1054G>A, c.1574+1G>A and c.282-1G>C), and 1 frameshift mutation 
(c.416_427del12ins16) (Table 3.1.4) 
We assume functional significance for the frameshift mutation c.416_427del12ins16, the 
splice site mutations c.1574+1G>A, c.282-1G>C and c.803G>C, the nonsense mutations 
p.R332X, p.Q157X, p.Q43X and p.R72X, and the point mutation c.1054G>A yielding two 
transcripts (see below). 
The MCCB missense mutations p.R155W, p.H190Y, p.H282R, p.V375F, p.G352R and 
p.A456V all change residues that are highly conserved (Baumgartner et al.. 2001; Desviat 
et al.. 2003; Jitrapakdee and Wallace, 2003). Furthermore, expression studies clearly 
demonstrate that the MCCB-p.H190Y and -p.G352R mutant alleles produce severely 
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decreased MCC activity confirming the deleterious functional consequences of these 
missense mutations (Table 3.1.5). 
 
Figure 3.1.1. Electropherograms showing the p.X564QLE missense mutation in the MCCB gene in 
proband 026. A corresponding control sequence is shown in the upper panel. The lower panel shows 
the heterozygous T>C substitution, changing the stop codon to a glutamine residue which results in 
a extension of the polypeptide by 3 amino acids at the C-terminus. 
 
Earlier studies have demonstrated that expression of MCCB-p.R155Q resulted in no 
detectable MCC activity (Baumgartner et al.. 2001). It is highly likely that the missense 
allele p.R155W also has deleterious consequences since it causes replacement of an 
arginine by a tryptophan at the very same position. The remaining missense mutation 
p.X564QLE changes the stop codon to a glutamine codon and consequently extends the 
encoded putative mutant MCC polypeptide by 3 amino acids at the C-terminus (Fig. 3.1.1). 
Since the C-terminal part of MCCβ is highly conserved, addition of 3 amino acids will 
likely interfere with normal functioning of the enzyme. Mutations of a similar type have 
been reported as causes of other monogenic disorders (Abe et al.. 2003; Marr et al.. 2002). 
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Table 3.1.4.
 
MCCB (MCCC2) mutant alleles and their consequences.
 
No. of 
alleles 
detected 
Nucleotide change at 
cDNA levela  
Exon / Intron Amino acid change Consequence 
(at RNA level) 
 
Reference 
3 c.295G>A exon 4 p.E99Q missense Baumgartner et al. 2001 
2 c.463C>T exon 5 p.R155W missense novel 
2 c.464G>A exon 5 p.R155Q missense Baumgartner et al. 2001 
2 c.568C>T exon 6 p.H190Y missense novel 
2 c.845A>G exon 9 p.H282R missense novel 
2 c.929C>G exon 10 p.P310R missense Baumgartner et al. 2001 
1 c.1123G>T exon 12 p.V375F missense novel 
2 c.1367C>T exon 14 p.A456V missense novel 
2 c.127C>T exon 1 p.Q43X nonsense novel 
1 c.214C>T exon 3 p.R72X nonsense novel 
2 c.469C>T exon 5 p.Q157X nonsense novel 
1 c.994C>Tb exon 10 p.R332X Nonsense (NMD) novel 
1 c.416_427del12ins16 exon 5 p.T139_G143>RW
VPGEfsX35 
frameshift novel 
2 c.517dupT exon 6 p.S173FfsX25 frameshift Baumgartner et al. 2001 
Gallardo et al. 2001 
2 c.282-1G>C intron 3 (p.G94_S127del) splice (skip exon 4) novel 
2 c.803G>C 
(r.785_803del) 
exon 8 p.R268T 
(p.G262_R268delfs
X5) 
splice Holzinger et al. 2001 
2 c.1054G>A 
(r.1054G>A + 
r.1000_1072delins 
r.999+858_r.999+992) 
exon 11 (p.G352R + 
p.V334_G358delins
KFFMKYFLRLDL
NSYNSTWQH) 
missense / splice 
(skip exon 11, insert  
64 bp from intron 10) 
novel 
3 c.1574+1G>Ab intron 16 (p.F497_V526>Gfs
X4) 
Splice (skip exon 16) novel 
1 c.1690T>C exon 17 p.X564QLE add 3 aa at C-terminus novel 
a 
cDNA variation numbering based on GenBank AF310971, with +1 as A of the ATG start codon; genomic reference 
sequence from intronic mutations is GenBank NM_022132. 
b Detected only after pre-incubation of cells with Emetine prior to isolation of RNA. 
NMD; nonsense-mediated mRNA decay. 
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In proband 021 genomic PCR of MCCB exon 8 revealed a G to C transversion at the last 
bp of exon 8 resulting in the known point mutation c.803G>C (p.R268T, Fig. 3.1.2A; 
Holzinger et al.. 2001). The present study demonstrates that this mutation causes a splicing 
defect in fibroblasts from proband 021. Direct sequencing of RT-PCR amplified cDNA 
revealed a homozygous frameshift mutation due to deletion of the last 19 bp of exon 8 (Fig. 
3.1.2B). We were not able detect the transcript with the c.803G>C change in 2 independent 
RT-PCR amplifications. The 3’base pair is conserved in about 80% of exons as a G 
(Shapiro and Senapathy, 1987) and contributes to donor splice recognition. Interestingly, a 
cytosine at this position appears to disrupt donor splice recognition leading to utilization of 
a cryptic splice donor site 19 bp upstream. Thus, the deleterious consequences of this 
missense mutation appear to be entirely due to the splicing defect. 
A further unusual finding was the partial replacement of MCCB exon 11 by an in frame 
insertion of a 64 bp sequence from intron 10 in proband 019 (Table 3.1.4). Sequence 
analysis of MCCB-RT-PCR cDNA showed two overlapping sequences. One transcript 
contained the normal 73 bp of exon 11 including the point mutation c.1054G>A (p.G352R), 
while the other transcript skipped exon 11, but instead inserted a 64 bp intronic sequence 
Table 3.1.5. Expressiona of MCCA (MCCC1) and MCCB (MCCC2) alleles. 
Experiment Allele Enzyme activityb 
(pmol/min/mg protein) 
  MCC PCC 
I MCCA-wild type 132 202 
 
MCCA-A291V 35 213 
 vector 0 287 
    
II MCCB-wild type 168 402 
 
MCCB-H190Y 0 364 
 
MCCB-G352R 18.4 337 
 vector 0 307 
a Transient transfection in SV40T-transformed reference MCCα- or MCCβ-deficient cell lines. 
b Numbers represent average of duplicates. 
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from intron 10. Genomic PCR of exon 11 indicated that this proband was homozygous for 
c.1054G>A. We hypothesize that the reduction in utilization of exon 11 associated with the 
c.1054G>A mutation is due to disruption of an exon splicing enhancer (ESE). Analysis of 
the MCCB ORF identified this motif as a putative exon splice enhancer sequence in an ESE 
prediction program (Fairbrother et al.. 2004). 
 
 
 
Figure 3.1.2. A: Genomic PCR of MCCB exon 8 in proband 021. The homozygous c.803G>C 
transversion of the last bp of exon 8 results in the missense mutation p.R268T. However, the 3’ base 
of an exon also contributes to donor splice site recognition. B: RT_PCR of MCCB cDNA in this 
proband resulted in a slightly smaller product due to utilization of a cryptic splice donor site (solid 
line). Use of this new splice donor site deletes the last 19 bp of exon 8 (dashed lines), which shifts 
the reading frame. 
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Finally, a survey of a European control population of 50 individuals was performed for 
all 4 MCCA (p.E134K, p.S187P, p.R232T and p.A291V) and all 7 MCCB missense alleles 
(p.R155W, p.R155Q, p.H190Y, p.H282R, p.P310R, p.V375F and p.A456V). None of them 
were identified in this collection of 100 control chromosomes indicating that each of these 
mutant alleles has a low frequency in this population. 
 In nine probands (004, 013, 025, 026, 027, 028, 029, 041 and 046) the steady state level 
of mRNA from the second allele was not detectable (Table 3.1.1 and 3.1.2) suggesting 
nonsense, framehift or splice site mutations that cause NMD. Contrary to conventional 
insights, the predominant consequence of nonsense mRNAs is not the synthesis of 
truncated proteins. Instead most mRNA molecules that contain a nonsense or frameshift 
mutation are highly unstable and are rapidly degraded by NMD (Frischmeyer and Dietz, 
1999). To identify possible mutations that cause NMD, the mutation analysis was repeated 
using cultured fibroblasts treated with Emetine prior to isolation of RNA. In three 
probands, this treatment allowed identification of the second mutant allele, i.e. MCCA-
c.1682-3A>G in proband 013 (Table 3.1.3), MCCB-p.R332X in proband 004 and MCCB-
c.1574+1G>A in proband 029 (Table 3.1.4) confirming that these mutations cause NMD. 
In proband 013 sequence analysis of MCCA-RT-PCR cDNA after Emetine treatment 
showed two overlapping sequences. One transcript contained the normal 50 bp of exon 15,  
while the other was 52 bp long with an insertion of AG. Genomic PCR of exon 15 indicated 
that the patient was heterozygous for an A>G transition at the –3 position in the splice 
acceptor site of intron 14 (c.1682-3A>G; TAAAG→TAGAG). A guanine at this position 
creates a cryptic splice acceptor site 2 bp upstream of the normal weak splice acceptor site. 
Utilization of this new acceptor splice site in fibroblasts from proband 013 causes insertion 
of two nucleotides (insAG), which shifts the reading frame. Finally, in proband 028 
sequence analysis of MCCA-RT-PCR cDNA after Emetine treatment showed clearly two 
alleles, one containing the already known p.R385S missense mutation, the other skipping 
exon 15. Genomic PCR of exons 15, 14 and 16 were repeatedly normal suggesting an 
intragenic deletion. Attempts to define this deletion using long range PCR failed. 
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Emetine studies could not be performed in five probands (025, 026, 027, 041 and 046) in 
whom a second mutant allele had not been identified. In these probands genomic PCR of all 
exons including flanking intronic sequences revealed one additional mutation in proband 
046, MCCA-p.C509SfsX38 (Table 3.1.3). In the remaining four probands we were not able 
to identify a second allele despite sequencing of all exons and flanking intronic sequences, 
suggesting that the steady state of mRNA from the second allele was not detectable as 
would be the case for a promotor mutation or an intragenic deletion or insertion missed by 
genomic PCR. 
Genotype-phenotype correlation? 
Based on small numbers, the present study failed to reveal any obvious genotype-
phenotype correlation. No mutations were exclusively present in symptomatic or 
asymptomatic probands. The majority of the 10 MCCα- and 18 MCCβ-deficient probands 
in this study carry private mutations with no common mutant allele for either gene. 
Combining this study with our earlier report (Baumgartner et al.. 2001), only one MCCA 
and two MCCB alleles occurred in more than 2 subjects in our 45 probands. First, the 
missense mutation MCCA-p.R385S, in spite of being the most prevalent so far, i.e. a total 
of 10 mutant alleles in 8 subjects (this study; Baumgartner et al.. 2001; Baumgartner et al.. 
2004; Gallardo et al.. 2001), appears not to be a predictor of a particular phenotype. 
Second, MCCB-p.S173FfsX75, which causes a truncation of the β-subunit, has been 
detected in proband 004, asymptomatic Swiss compound heterozygote (Gitzelmann et al.. 
1987; Baumgartner et al.. 2001), but also in two asymptomatic Amish/Mennonite adult 
homozygotes (Gibson et al.. 1998; Gallardo et al.. 2001). Third, the missense mutation 
MCCB-p.E99Q has been detected in a Turkish child with fatal outcome and an adult Amish 
patient with only mild symptoms (Bannwart et al.. 1992; Baumgartner et al.. 2001). Each of 
these mutations has also been detected in so far asymptomatic newborns (this study). Only 
time will tell whether these subjects receiving careful management will remain 
asymptomatic. As a word of caution, it has to be stated that there is no well-defined 
phenotype for MCC deficiency and therefore there is the possibility that some of the 
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literature reports of MCC-deficient patients with various neurological problems simply 
reflect bias of ascertainment.  
In total, we have now investigated 45 MCC-deficient probands, 21 of whom were 
detected by newborn screening. Clinical, biochemical and genetic data strongly support the 
idea that factors other than the genotype at the MCC loci, such as modifying genes and 
environmental factors, must have a major influence on the phenotype of MCC deficiency. 
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3.2. Consanguineous 3-methylcrotonyl-CoA carboxylase deficiency: early-onset 
necrotizing encephalopathy with lethal outcome 
Baykal T, Humer Gokcay G, Ince Z, Dantas MF, Fowler B, Baumgartner MR, Demir F, Can G, 
Demirkol M. J. Inherit. Metab. Dis. 28(2):229-33 2005 
 
Abstract 
A patient with a severe neonatal variant of 3-methylcrotonyl-CoA carboxylase (MCC) 
deficiency is reported. The first child of healthy consanguineous Turkish parents presented 
on the second day of life with dehydration, cyanosis, no sucking, generalized muscular 
hypotonia, encephalopathy, respiratory depression requiring mechanic ventilation, 
macrocephaly, severe acidosis and hypoglycaemia. Elevated C5-OH-carnitine in dried 
blood spot by tandem MS and elevated urinary excretion of 3-hydroxyisovaleric acid and 3-
methylcrotonylglycine suggested MCC deficiency, confirmed by enzyme analysis in 
cultured fibroblasts. Cerebral ultrasonography and cranial CT findings revealed progressive 
changes such as disseminated encephalomalacia, cystic changes, ventricular dilatation and 
cerebral atrophy. Treatment with high-dose biotin and protein-restricted diet was ineffective 
and the patient died at the age of 33 days with progressive neurological deterioration. 
Mutation analysis revealed a homozygous mutation in the splice acceptor site of intron 15 
in the MCCβ-subunit. Early-onset severe necrotizing encephalopathy should be included in 
the differential diagnosis of isolated MCC deficiency. 
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Introduction 
3-Methylcrotonyl-CoA carboxylase (MCC, EC 6.4.1.4) deficiency is an inborn error of 
leucine catabolism with autosomal recessive inheritance. Isolated MCC deficiency is 
caused by mutations in either MCCA (McKusick 210200) or MCCB (McKusick 210210), 
which encode the a- and b- subunits of MCC, respectively. The clinical course ranges from 
severe to benign forms.  
Patients with MCC deficiency usually have normal growth and development until they 
present with an acute episode between 6 months and 3 years of age. The episodes 
frequently follow minor infections and involve feeding difficulty, vomiting, lethargy, 
apnoea, muscle hypotonia and seizures. Typical laboratory findings of an acute episode are 
severe hypoglycaemia, hyperammonaemia, elevated hepatic transaminases, mild metabolic 
acidosis and moderate ketonuria. Detection of elevated 3-hydroxyisovaleric acid (3-HIVA) 
and 3-methylcrotonylglycine (3-MCG) in urinary organic acids by gas chromatography--
mass spectrometry (GC-MS) is diagnostic and may occur without elevation of 
isovalerylglycine or the distal leucine metabolites (Sweetman and Williams 2001). The 
analysis of acylcarnitines in dried blood samples by tandem MS consistently shows 
elevated 3-hydroxyisovalerylcarnitine. 
Case Report 
The patient was a male infant born post maturely at the gestational age of 44 weeks, with 
normal spontaneous delivery at home. He was the first child of healthy Turkish parents who 
were first cousins once removed. The family history is otherwise unremarkable. There was 
absence of sucking or crying during the first day. He was brought to our hospital at the age 
of 31 h. Anthropometric evaluation showed a body weight of 3.5 kg (75th centile), height 
51 cm (50th centile) and head circumference 38 cm (97th centile). Physical examination 
revealed dehydration, cyanosis, encephalopathy, respiratory depression and poor capillary 
circulation. Neonatal reflexes were depressed and hypertonic episodes were observed in 
spite of prominent hypotonia. He was intubated immediately and put on mechanical 
ventilation in the neonatal intensive care unit. After cultures had been taken, antibiotics and 
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intravenous fluids were started, with a presumptive diagnosis of sepsis. Within an hour of 
hospital admission, cardiac arrest occurred with re-establishment of circulation after 2^3 
min of resuscitation. Biochemical evaluation showed metabolic acidosis (pH 7.3, BE _15.3 
mEq/L, Pco217.5mm/Hg), hypoglycaemia (glucose 36 mg/dl) and hyperlactataemia (5.7 
mmol/L, normal < 2). Urinary organic acid determination by GC-MS revealed elevated 
lactic acid, 3-HIVA, 3-MCG and 3-hydroxybutyric acid. Acylcarnitines and amino acids by 
tandem MS disclosed elevated C5-OH-carnitine, normal free carnitine and normal amino 
acids profile in dried blood spots. Plasma biotinidase activity was normal (4.59 nmol/min 
per ml, normal 4.2^8.4). Sepsis work-up, blood and CSF cultures were negative. Cerebral 
ultrasonography showed cerebral oedema on the second day of admission and mannitol 
therapy was given for a short duration. EEG demonstrated disseminated amplitude 
depression. Doppler ultrasonography (US) (on the 7th day of admission) showed decreased 
cerebral blood flow, progression of oedema and ventricular dilatation.  
At the age of 3 weeks, depression of the cranial bones was observed and repeated 
cerebral US showed cystic changes and leukodystrophy. Cranial CT was planned because 
of the progression in cerebral US findings. Disseminated encephalomalacia, multiple cysts, 
ventricular dilatation and cerebral atrophy were observed. The infant was treated with 
protein-restricted diet (1 g/kg per day), high-dose biotin (30--60 mg/day) and carnitine (100 
mg/kg per day) supplementation. There was no clinical or bio-chemical improvement with 
this treatment; the baby could not come off the ventilator and he was lost at the age of 33 
days 
Material and Methods 
Urinary organic acid determination was performed by GC-MS. The activities of biotin-
dependent carboxylases were determined in fibroblasts, cultured in media containing 
different amounts of biotin, by measuring the incorporation of [14C]bicarbonate into acid 
nonvolatile products as previously described (Suormala et al. 1985). Mutational analysis 
was performed by amplification of cDNA from fibroblast RNA followed by direct 
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sequencing and confirmation of identified mutations on genomic DNA as described 
(Baumgartner et al. 2001). 
Results 
Table 3.2.1 shows the urinary excretion of 3-HIVA and 3-MCG detected with different 
biotin dosages and dietary protein intake. There was no clinical or biochemical response to 
therapy. While MCC activity was undetectable, the other two biotin-dependent 
carboxylases had activities in the normal range in cultured fibroblasts (Table 3.2.2). RT-
PCR amplification and direct sequencing of MCCB cDNA resulted in a smaller product 
than wild-type owing to exon 16 skipping. Amplification of MCCB exon 16 from genomic 
DNA revealed a homozygous mutation in the splice donor site of intron 16 (IVS16+1G>A). 
 
Table 3.2.1. Urinary excretion of 3-hydroxyisovaleric acid (“-HIVA) and 3-Methylcrotonylglycine 
 (3-MCG) under biotin and dietary therapy.
 
 
 
 
 Age 
(days) 
Urinary organic acid 
 excretion 
3-HIVA                    3-MCG 
        (mol/mol                  (mol/mol 
       creatinine)               creatinine) 
 
 
 
Biotin suppementation 
(mg/day) 
 
 
 
Dietary therapya 
2 0.153 0.044 - Breast milk 
18 6.703 13.653 30 Breast milk 
21 5.267 9.389 40 Protein restriction: 
0 g protein/kg per/day 
Energy: 440kJ/kg per day 
29 1.084 1.073 60 Protein restriction: 
1 g protein/kg per/day 
Energy: 440kJ/kg per day 
aGiven with a nasogastric tube 
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Discussion 
Patients with MCC deficiency show variable clinical phenotypes ranging from 
asymptomatic adults to severe neonatal phenotypes, leading to coma and death  in early 
infancy. This patient was born post maturely with macrocephaly. He was apathic soon after 
birth, did not cry and rejected feeding. The severity of clinical and biochemical 
abnormalities including lactic acidosis raised the suspicion of holocarboxylase synthetase 
deficiency, but the absence of 3-hydroxypropionic aciduria points to isolated MCC 
deficiency even in such severe cases. Very few patients with early-onset MCC deficiency 
have been reported (Bannwart et al. 1992; Lehnert et al. 1996). They had seizures, 
Table 3.2.2. Activities of biotin-dependent carboxylases in cultured fibroblats. 
   Carboxylase activity (pmol / min per mg protein) at given 
biotin concentration 
 
 0.1 nmol/L          10 nmol/L           10 µ mol/L          10µ mol/L 
       NBa                              FCSb                   NB                     FCS 
Propionyl-CoA carboxylase     
Patient 216 637 346 647 
Control (n = 31, range) 183-1451 287-2150 201-1513 302-1600 
Methylcrotonyl-CoA 
carboxylase  
 
 
  
Patient NDc ND 0.6 ND 
Control (n = 31, range) 52-642 160-696 120-776 130-647 
Pyruvate carboxylase      
Patient 183 489 360 476 
Control (n = 31, range) 207-2373 229-2660 240-1845 225-2753 
aNB, newborn calf serum 
bFCS, fetal calf serum 
cND, not detectable 
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hypotonia, failure to thrive, hypoglycaemia and metabolic acidosis in the neonatal period. 
Our patient had the earliest presentation of all MCC cases reported to date. We recognize, 
however, that our patient is the product of a consanguineous union and could have an 
additional genetic disorder that was not detected, despite comprehensive evaluation. 
Cranial MRI changes in isolated MCC deficiency are reported as marked brain atrophy 
in a 15-year-old patient and multiple foci of leukodystrophy in a 14-month-old patient 
(Kremer et al. 2002; Murayama et al. 1997). The striking cranial imaging findings of our 
patient included severe encephalomalacia, leukodystrophy, cystic lesions, ventricular 
dilatation and cerebral atrophy, indicating a rapid progression within the newborn period. 
During the last week of his life, this necrotizing encephalomalacia, even manifested as 
depression of cranial bones, was evident on physical examination. 
MCC is a heteromeric mitochondrial enzyme composed of biotin-containing α-subunits 
and smaller β-subunits (Baumgartner et al. 2001). Mutation analysis revealed a 
homozygous mutation in the splice donor site of intron 16 in MCCB. The functional 
consequences of this splice site mutation can be assumed to be deleterious, as suggested by 
undetectable MCC activity in cultured fibroblasts. The patient with severe phenotype and 
early onset described by Bannwart and colleagues was homozygous for another mutation in 
MCCB, the missense mutation E99Q, and was reported as proband 002 (Baumgartner et al. 
2001). According to our current knowledge, most patients carry private mutations 
(Baumgartner et al. 2001). 
These observations add early-onset severe necrotizing encephalopathy to the spectrum of 
clinical abnormalities in isolated MCC deficiency. 
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3.3. Isolated biotin resistant 3-methylcrotonyl-coenzyme A carboxylase deficiency 
in a child with metabolic stroke. 
Pinto LLC, Zen P, Rosa R, Paskulin G, Perla A, Barea L, Baumgartner MR, Dantas MF, Fowler B, 
Giugliani R, Vargas CR, Wajner M, Graziadio C. J. Inherit. Metab. Dis. in press 
 
Isolated biotin resistant 3-Methylcrotonyl-CoA carboxylase (MCC; EC 6.4.1.4) 
deficiency (McKusic 210200 and 210210) is an autosomal recessive disorder of leucine 
catabolism (Baumgartner et al.. 2001). The clinical phenotype is highly variable. We report 
a 3-year-old boy with isolated MCC deficiency that had a unexpectly severe presentation 
with seizures and a history of a cerebral ischemic episode.   
The patient is the second child of healthy non-consanguineous Brazilian parents, and 
was born at term after an uneventful pregnancy and delivery. His birth weight was 2800 g 
(P10), length 47 cm (P3), and head circumference 34 cm (P25-50). At the age of 5 months 
he presented hypotonia and developed seizures unresponsive even to high doses of 
anticonvulsants. Psychomotor retardation was observed at 8 months. CT and MRI scans of 
the brain showed a hypodense perisilvian right lesion corresponding to an ischemic event. 
On admission with 10 months, he had persistent seizures, failure to thrive and feeding 
problems and the physical exam showed a left hemiplegia. At 12 months his development 
was that of a child of 4 months and he was referred for genetic evaluation of epilepsy. At 
this time his weight was 9875 g (P3-10), his length 79 cm (P50) and his head circumference 
44 cm (P2). He had a broad forehead and clinodactyly of 5th fingers. Generalized 
hypotonia and mild left hemiplegia were observed. Electroencephalogram (EEG) showed 
generalized spikes and polyspikes, and burst suppression in the background activity. 
Echocardiography was normal.  
Laboratory investigation revealed normal values for white cells, blood gases, lactate, 
plasma glucose and transaminases. Organic acid analysis (by GC/MS) revealed increased 
excretion of 3-hydroxyisovaleric acid (3-HIVA) and 3-methylcrotonylglycine (3-MCG). 
Plasma biotinidase was normal. Enzyme studies were performed. Carboxylase activities in 
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fibroblast homogenates were determinate by measuring the incorporation of 14C-
bicarbonate into acid nonvolatile products. MCC activity was 4 pmol/min./mg protein 
(normal: 160-969) and propionyl-CoA carboxylase (PCC) activity was 424 pmol/min/mg 
protein (normal: 287-2150). Thus these results showed markedly decreased activity of 
MCC while the activity of PCC was in the normal range allowing the diagnosis of isolated 
3-methylcrotonyl-CoA carboxylase deficiency. To detect mutant alleles we performed RT-
PCR amplification of MCCA and MCCB cDNAs. Direct sequencing of the products 
revealed that the patient is homozygous for a missense mutation in exon 5 of MCCB that 
replaces an arginine by a tryptophan (MCCB-p.R155W). The result was confirmed by 
amplification of MCCB exon 5 by genomic PCR (Dantas et al. 2005).  
He was treated with low protein diet (1g/kg/d) for 4 months and L-carnitine (100 
mg/kg/d) as soon the diagnosis was made. After 2 years receiving L-carnitine, physical and 
psychomotor developments were improved. By the age of 2 years and 10 months he was 
starting to walk and speaking no more than 3 words. At present he is still receiving L-
carnitine 100 mg/kg/d. 
Another patient with isolated MCC deficiency associated with metabolic stroke has been 
reported by Steen et al.. (1999). Our patient is a second example of this confirming that a 
“metabolic stroke” can occur in MCC deficiency. Moreover, this case underlines the 
importance of prompt screening for organic acidurias in acute focal brain disease.  
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4. Consequences of MCCA and MCCB missense mutations on MCC 
activity, and analysis of steady-state levels of mutant MCCα protein. 
The spectrum of mutations of MCC-deficient patients shows a majority of missense 
mutations in both MCCA and MCCB genes, but also a large number of nonsense, frameshift 
and splice site mutations. We assume functional significance for splice and nonsense 
mutations, and for deletions and insertions that change the reading frame. In order to 
confirm the pathogenic effect of MCCA and MCCB missense mutations, we show the 
functional consequences of 1 MCCA and 3 MCCB missense alleles using transient 
transfection of mutant constructs into SV40T-transformed reference MCCA or MCCB 
deficient cell lines followed by measurement of MCC activity. In addition, Western blotting 
was used to analyze the effect of different mutations on the stability of the MCCα protein. 
The apparent severity of MCC mutations contrasts with the variety of clinical phenotypes 
found in MCC-deficient patients, suggesting that factors other than the genotype at the 
MCC loci have a major influence on the resulting phenotype.  
Material and Methods 
Construction of wild type and mutant MCCA and MCCB expression vectors 
The full-length wild type MCCA (-51 to +2275), wild type MCCB (-99 to +1824), and 
MCCA and MCCB containing the missense mutations to be analysed, were amplified from 
control and MCC-deficient patient RNA and TOPO TA cloned into pCR 2.1 TOPO vector 
(Invitrogen Corp. Basel, Switzerland). The MCCA-p.A291V, MCCB-p.H190Y, MCCB-
p.G352R and MCCB-p.X564QLE mutant constructs were then transferred into the 
mammalian expression vector pTracer-CMV2 (Invitrogen Corp. Basel, Switzerland) at the 
EcoR I site. This vector contains a green fluorescent protein gene fused to the Zeocin 
resistance gene. All constructs were sequenced in both directions to validate the sequences.  
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Transfections 
The constructs indicated above were electroporated into either SV40T-transformed 
MCCA (homozygous for MCCA-p.Q421fs+1) or MCCB (homozygous for MCCB-p.S173L) 
deficient cell lines as described previously (Baumgartner et al. 2001, Dantas et al. 2005). 
Briefly, 20-30 µg of plasmid DNA were transfected into 1.2x10-7  cells using a Gene Pulser 
II electroporator (Bio-Rad, Reinach, Switzerland) set at 250 V and 950 µF. The cells were 
harvested 72 hours after transfection and assayed for MCC and PCC activities. Transfection 
with vector alone was used as a negative control. MCC activity obtained after transfection 
with vector containing the corresponding wild type MCC allele was used as a positive 
control.  
Western Blot analysis of MCCα protein 
Proteins were extracted from fibroblast homogenates of patients with MCCA mutations 
using M-PER Mammalian Protein Extraction Reagent (Pierce, Rockford, IL, USA). Protein 
content was measured using the BCA protein assay (Pierce, Rockford, IL, USA). Equal 
amounts of protein (20 µg/well) were applied on a 10% Tris-HCl precast gel, and 
electrophoresis was performed at 100 V for 90 minutes (Bio-Rad, Reinach, Switzerland). 
Proteins were transferred onto a nitrocellulose membrane (Bio-Rad, Reinach, Switzerland). 
Membranes were incubated in blocking buffer (Tris buffered saline pH 7.4, 0.5% non fat 
dry milk) for 30 minutes, and then incubated with MCCα antiserum (kindly supplied by 
Prof. D. Valle) at room temperature for 1 hour. After several washings, membranes were 
incubated with peroxidase-conjugated Anti-Rabbit IgG (Jackson Immuno Research 
Laboratories, USA). Immunoblots were visualized by chemiluminescence using Super 
Signal (Pierce, Rockford, IL, USA).   
Results and Discussion 
 
Functional characterization of MCCA and MCCB missense alleles 
The molecular effect of missense mutations is difficult to predict, whereas the 
pathogenicity of nonsense, frameshift or splice mutations is generally assumed as they are  
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predicted to result in truncated proteins. In order to confirm that a missense mutation is 
responsible for MCC deficiency, we have used transient transfection of transformed MCCA 
and MCCB deficient cell lines to investigate the effect of 1 MCCA (p.A291V) and 3 MCCB 
(p.H190Y, p.G352R, p.X564QLE) missense mutations.  
As shown in Table 1 MCC activity was not detectable or severely decreased in the three 
MCCβ missense alleles expressed, whereas the MCCA-p.A291V mutant allele showed 26% 
of wild-type activity (Figure 4.1). Regarding MCCB alleles, the missense mutations 
p.G352R and p.X564QLE  result in low levels of activity (11% and 9%, respectively) while 
the missense allele p.H190Y showed no MCC activity (Figure 4.1). These results provide 
evidence that three of the above mentioned missense alleles are pathogenic and cause MCC 
deficiency. Transfection efficiency, assessed by scoring a subset of cells in each 
transfection for the presence of the coexpressed GFP, ranged from 10 to 20% in these 
experiments. 
The mutant allele MCCB-p.G352R involves a glycine at position 352 of the MCCβ  
protein which is highly conserved and maps to a region probably responsible for binding of 
3-methylcrotonyl-CoA (Baumgartner et al. 2001, Desviat et al. 2003). Substitution at this 
position by an arginine may destabilize the region and reduce substrate binding accounting 
for the loss of function. The missense mutation MCCB-p.X564QLE changes the stop codon 
to a glutamine codon and consequently extends the encoded putative mutant MCC 
polypeptide by 3 amino acids at the C-terminus (Dantas et al. 2005). Since the C-terminal 
part of MCCβ is highly conserved, addition of 3 amino acids will likely interfere with 
normal function of the enzyme. Mutations of a similar type have been reported as causes of 
other monogenic disorders (Abe et al., 2003; Marr et al., 2002). Regarding the missense 
allele MCCB-H190Y the histidine residue at the position 190 is not strictly conserved, 
however the tyrosine mutant residue is not present in the homologous proteins 
(Baumgartner et al. 2001, Desviat et al. 2003).  
 Regarding the MCCA-p.A291V missense allele, the alanine at position 291 of the 
MCCα protein is highly conserved. A change to a valine at this position can be considered 
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as a mild change since both amino acids are aromatic and non-polar. This could explain the 
relatively high level of  residual activity detected (26%). 
 
 
Figure 4.1. Expression of wild type (WT), MCCA-p.A291V and MCCB-p.H190Y, MCCB-
p.G352R and MCCB-p.X564QLE missense alleles. 3-Methylcrotonyl-CoA carboxylase (MCC) and 
propionyl-CoA carboxylase (PCC) activity is expressed as % of WT.  
Table 4.1.
 
Expressiona of MCCA and MCCB alleles.
 
 
a Transient transfection in SV40T-transformed reference MCCα- or MCCβ-deficient cell lines. 
b Numbers represent average of duplicates. 
Gene Allele Enzyme activityb 
(pmol/min/mg protein) 
References 
  Experiment 1 Experiment 2  
  MCC PCC MCC PCC  
MCCA wild type 132 202 - -  
 A291V 35 213 - - Dantas et al. 2005 
 vector 0 287 - -  
       
MCCB wild type 168 402 115 634  
 H190Y 0 364 - - Dantas et al. 2005 
 G352R 18.4 337 - - Dantas et al. 2005 
 X564QLE - - 10 543 Not Published 
 vector 0 307 0 466  
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Western Blot Analysis 
To analyze the MCC polypeptides under steady-state condition in fibroblasts of MCCA 
deficient patients, we carried out Western blot analysis using rabbit anti-human MCCα 
antiserum. The results are shown in Figure 4.2. The MCCα protein (79 kDa) was readily 
detected in fibroblasts from wild type control (lane 1) and from a MCCB-deficient patient 
(compound heterozygous for MCCB-p.R332X and MCCB-p.S173FfsX25 (lane 2), and was 
absent in a negative control cell line homozygous for MCCA-Q421AfsX10 (lane 3). The 
MCCα protein was missing in fibroblasts of patients 036 (homozygous for p.C509X; lane 
4), 043 (compound heterozygous for p.G214IfsX5 and p.E644X; lane 5), 046 (compound 
heterozygous for p.V697SfsX19 and p.C509SfsX38; lane 6), 050 (homozygous for 
p.E628X; lane 7), and 060 (homozygous for p.T693TfsX1; lane 8). All these mutations 
result in a truncated protein due to formation of premature termination codon (PTC) which 
usually leads to nonsense mediated mRNA decay (NMD).  
In patients 041 (lane 9) and 064 (lane 10) only one mutant allele could be identified in 
the RT-PCR products (MCCA-p.R232W and MCCA-p.P632S, respectively). The second 
allele could not be detected indicating instability of this mutant allele and consequent 
degradation by the mechanisms of NMD. Usually, RNAs transcribed from mutant alleles or 
resulting from defective processing events in the nucleus are rapidly degraded to ensure cell 
growth. This is particularly important for mutations that give rise to a PTC upstream of the 
normal stop codon, as translation would yield a C-terminal truncated polypeptide. Such 
polypeptides can often act in a dominant-negative manner, leading to deleterious effects on 
the cell or organism. Fortunately, the eukaryotic cell has in place a surveillance mechanism, 
the NMD pathway, to ensure that only error-free mRNAs are accurately translated (Hentze 
and Kulozik 1999). 
 The MCCα protein was readily detected in normal amount and size in fibroblasts of five 
MCCA deficient patients, i.e. 020 (compound heterozygous for p.R385S and p.S187P; lane 
11), 028 (compound heterozygous for p.R385S and exon 15 skipping due to an intragenic 
deletion, lane 12), 031 (compound heterozygous for p.R385S and p.E134K; lane 13), 053 
(homozygous for p.R385S; lane 14), and 057 (homozygous for p.E288G; lane 15).    
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The missense mutation MCCA-p.R385S is unusual in that it is the only tested missense 
allele for which Western blot analysis shows normal amounts of MCCα protein 
(Baumgartner et al. 2001, Gallardo et al. 2001). In contrast, western blot analysis of the 
MCCα protein was normal in amount and size in 4 patients carrying MCCA-p.R385S. This 
is in agreement with previous studies which show that the protein product of this allele is 
stable (Baumgartner et al. 2001, Gallardo et al. 2001).  
 
Figure 4.2. Western blot analysis of MCCα protein of wild type (lane 1), a MCCB-deficient patient 
(lane 2), a negative control for MCCα protein (lane 3), and 12 MCCA-deficient patients (lane 4 to 
15). Equal amounts of total fibroblast protein (20 µg) from each sample were loaded on a 10% Tris-
HCl precast gel and MCCα protein was detected using affinity purified MCCα antiserum as 
described in Methods. The identification of MCCα was determined by its mobility compared with 
protein standards for blotting and its absence in negative control. 
 
 
 
 
 
 
 
 
 
1 2 3 4 5 116 1297 14 15138 10
MCCα MCCα
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5. Investigation of molecular defects with dominant-negative effect on MCC 
activity.  
The majority of enzyme deficiencies are inherited as autosomal recessive traits. The 
terms dominant and recessive refer to the clinical phenotype associated with a particular 
allele (Beaudet et al. 2001). Although a recessive phenotype is defined as being clinically 
undetectable in heterozygotes, heterozygotes for many of these conditions exhibit subtle 
differences in phenotype when examined at the cellular or biochemical level, and these 
differences may be enhanced by environmental factors (Beaudet et al. 2001). Even when 
clinically normal, individuals who are heterozygous for recessive loss-of-function alleles 
demonstrate metabolic differences at the protein level. Such subtle phenotypic effects may 
be more common than is generally recognized and may contribute to phenotypes usually 
considered to be complex traits (Beaudet et al. 2001). 
In 1987, Herskowitz described the term dominant-negative effect as a mutant allele in a 
heterozygote fashion (or, for X-linked traits, hemizygote) that interferes in one or another 
way with the function of the normal protein. In general, most dominant-negative mutations 
are considered as an altered function allele or as a particular subset of gain-of-function 
allele. These effects occur when proteins are stable and involved in subunit structures, or 
when these proteins interact with a nucleic acid or another protein in a complex. This will 
lead to the formation of non-functional multimers  (Herskowitz 1987). Such a mutant allele 
has a dominant effect because its phenotype is manifested despite the presence of the wild-
type allele.  
Excellent examples of complex mechanisms that can underlie dominant-negative alleles 
can be found in the case of collagen and osteogenesis imperfecta, where many missense 
mutations interfere with fiber assembly and cause lethal osteogenesis imperfecta type II in 
heterozygotes, while null alleles cause a much milder form of the disease (Byers and Cole 
2002). Heterozygosity for cystathionine β-synthase deficiency homocystinuria is also a risk 
factor in vascular disease (Clarke 2002), dementia in Alzheimer disease (Loscalzo 2002), 
and osteoporotic fractures in the elderly (Raisz 2004). 
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Our laboratory received two patient cell lines (047 and 048) with suspected MCC 
deficiency, which were shown to have partial MCC deficiency in cultured fibroblasts (20 
and 21% of mean control value, respectively). Despite high residual MCC activity in vitro, 
we sequenced the entire ORF of MCCA and MCCB, and found that both patients are 
heterozygous for MCCA-p.R385S, but do not have any other coding alterations. 
 R385S is a missense mutation that changes an arginine to a serine at position 385 in the 
MCCα protein. This missense allele is of particular interest, because the mutant protein is 
stable and because the residue corresponding to MCCA-p.R385S is predicted to be part of a 
positively charged pocket for bicarbonate binding in the structure of the biotin carboxylase 
domain of E. coli ACC. 
In the following chapter we provide evidence that MCCA-R385S is a dominant negative 
missense allele, and can lead to biochemical abnormalities and clinical symptoms in 
heterozygous individuals. 
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5.1. Isolated 3-methylcrotonyl-CoA carboxylase deficiency: evidence for an allele 
specific dominant negative effect and responsiveness to biotin therapy 
Baumgartner MR, Dantas MF, Suormala T, Almashanu S, Giunta C, Friebel D, 
Gebhardt B, Fowler B, Hoffmann GF, Baumgartner ER, Valle D. Am. J. Hum. Genet. 
75:790-800 2004 
Abstract 
Deficiency of 3-methylcrotonyl-CoA carboxylase (MCC) results in elevated excretion of 
3-methylcrotonylglycine (3-MCG) and 3-hydroxyisovaleric acid (3-HIVA). MCC is a 
heteromeric mitochondrial enzyme comprising biotin containing α subunits and smaller β 
subunits, encoded by MCCA and MCCB, respectively. Mutations in these genes cause 
isolated MCC deficiency, an autosomal recessive disorder with a variable phenotype that 
ranges from severe neonatal to asymptomatic adult forms. No reported patients have 
responded to biotin therapy. Here, we describe two patients with a biochemical and, in one 
case, clinical phenotype of MCC deficiency, both of whom were responsive to biotin. The 
first patient presented at 3 months with seizures and progressive psychomotor retardation. 
Metabolic investigation at 2 years revealed elevated excretion of 3-MCG and 3-HIVA, 
suggesting MCC deficiency. High-dose biotin therapy was associated with a dramatic 
reduction in seizures, normalization of the electroencephalogram, and correction of the 
organic aciduria, within 4 weeks. MCC activity in fibroblasts was 25% of normal levels. 
The second patient, a newborn detected by tandem-mass-spectrometry newborn screening, 
displayed the same biochemical phenotype and remained asymptomatic with biotin up to 
the age of 18 months. 
In both patients, sequence analysis of the complete open reading frames of MCCA and 
MCCB revealed heterozygosity for MCCA-p.R385S and for the known polymorphic variant 
MCCA-p.P464H but revealed no other coding alterations. MCCA-p.R385S is unusual, in 
that it has a normal amount of MCCA protein but confers no MCC activity. We show that 
MCCA-p.R385S, but not other MCCA missense alleles, reduces the MCC activity of 
cotransfected MCCA–wild-type allele. Our results suggest that MCCA-p.R385S is a 
dominant negative allele and is biotin responsive in vivo. 
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INTRODUCTION 
3-methylcrotonyl-CoA carboxylase (MCC [Enzyme Commission number 6.4.1.4]) is a 
biotin-dependent enzyme that catalyses the fourth step in the leucine catabolic pathway. It 
carboxylates 3-methylcrotonyl-CoA to 3-methylglutaconyl-CoA in an ATP-requiring 
reaction that uses bicarbonate as the source of the carboxyl group (Sweetman and Williams 
2001). MCC is a member of the family of biotin-dependent carboxylases, a group of 
enzymes with diverse metabolic functions but common structural features (Samols et al. 
1988, Wolf 2001). In addition to MCC, there are three other biotin-dependent carboxylases 
in humans: propionyl-CoA carboxylase (PCC), pyruvate carboxylase, and acetyl-CoA 
carboxylase (Samols et al. 1988, Wolf 2001). Biotin is covalently bound to the 
apocarboxylases by holocarboxylase synthetase (HCS [GenBank accession number 
BC060787]) and, after proteolytic degradation of the active holocarboxylase into short 
biotinyl peptides or biocytin, it is released by biotinidase, enabling the recycling of biotin 
(Wolf 2001). MCC deficiency is caused either by defects of the MCC enzyme itself or by 
deficient activity of the enzymes involved in the metabolism of its cofactor biotin — that is, 
the enzymes HCS or biotinidase — deficiencies of which cause multiple carboxylase 
deficiency. 
Isolated biotin-resistant MCC deficiency (also known as “methylcrotonylglycinuria” 
[MIM 210200 and 210210]) is inherited as an autosomal recessive trait (Sweetman and 
Williams 2001). The clinical phenotype is highly variable. Some patients present in the 
neonatal period with seizures and hypotonia (Bannwart et al. 1992, Lehnert et al. 1996), 
others are asymptomatic adult women discovered only by detection of abnormal 
metabolites in the neonatal-screening samples from their healthy babies (Gibson et al. 
1998). Most patients are asymptomatic until an episode of acute metabolic decompensation 
after intercurrent illness in early childhood, which leads to their diagnosis. These patients 
usually respond to intravenous fluids and the cessation of protein feeding and are 
asymptomatic between episodes. Some children have been placed on a leucine restricted 
diet supplemented with oral L-carnitine, but the efficacy of this approach is unproven. In 
contrast to patients with multiple carboxylase deficiency due to HCS or biotinidase 
deficiency, no reported patient has been biotin-responsive, defined as showing a significant 
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clinical and/or biochemical improvement in response to oral administration of biotin at 
doses of 1–2 mg/kg/d or higher. 
Patients with MCC deficiency have a characteristic organic aciduria with greatly 
increased excretion of 3-hydroxyisovaleric acid (3-HIVA) and 3-methylcrotonylglycine (3-
MCG), usually in combination with severe secondary carnitine deficiency. In addition, 
acyl-CoA derivatives accumulate and are trans-esterified to acylcarnitine esters; the major 
abnormal metabolite, 3-hydroxyisovalerylcarnitine, is found in blood and urine (Sweetman 
and Williams 2001). It is surprising that MCC deficiency appears to be the most frequent 
organic aciduria detected in tandem mass spectrometry (TMS) newborn-screening 
programs in North America (Naylor and Chace 1999, Koeberl et al. 2003), Europe 
(Roscher et al. 2000, Schulze et al. 2003), and Australia (Wilcken et al. 2003). 
Isolated MCC deficiency can be confirmed by demonstration of deficient MCC activity 
in the presence of normal activity of another biotin-dependent carboxylase in cultured skin 
fibroblasts or in isolated lymphocytes. MCC activity in cultured fibroblasts of patients is 
usually !2% of the mean control value. Two patients with higher residual activity, varying 
from 4% to 12%, in cultured fibroblasts have been reported elsewhere (Tuchman et al. 
1993, Wiesmann et al. 1998). No correlation between the level of residual enzyme activity 
and clinical presentation has been observed.  
Bovine MCC has a size of 835 kDa and appears to comprise six heterodimers: (αβ)6 
(Lau et al. 1980). MCC is predominantly localized to the inner mitochondrial membrane. 
Like PCC, MCC is composed of larger α-subunits, which covalently bind biotin, and 
smaller β-subunits, encoded by the MCCA (MCCC1 [GenBank accession number 
BC004214]) and MCCB (MCCC2 [GenBank accession number BC065027]) genes, 
respectively, which have been cloned and characterized (Baumgartner et al. 2001, Gallardo 
et al. 2001, Holzinger et al. 2001). To date, 1 functionally neutral polymorphic variant, 9 
functionally significant mutant MCCA alleles, and 13 functionally significant mutant 
MCCB alleles have been reported in probands with severe MCC deficiency (Baumgartner 
et al. 2001, Gallardo et al. 2001, Holzinger et al. 2001, Obata et al. 2001, Desviat et al. 
2003). Several affected sibs of symptomatic patients have been clinically normal (Beemer 
 63 
et al. 1982, Jurecki and Packman 1992, Mourmans et al. 1995), suggesting that the 
genotypes at the MCCA and MCCB loci are not the sole determinants of the clinical 
phenotype. 
One of the identified missense alleles, MCCA-p.R385S, is unusual in that it is the only 
one of seven missense alleles detected in six MCCα-deficient patients for whom protein-
blot analysis of fibroblast homogenates shows the presence of MCCα protein (i.e., shows 
cross reactive material [CRM]) (Baumgartner et al. 2001, Gallardo et al. 2001). Indeed, 
these studies suggest that the amount of MCCα protein in fibroblasts from a patient 
homozygous for the MCCA-p.R385S allele is normal or greater than normal, whereas six 
other MCCA missense alleles had little or no detectable CRM (Baumgartner et al. 2001). 
MCCA-p.R385S appears to be the most frequent allele found in MCC-deficient patients of 
German origin. Of seven such patients, one is homozygous and six are compound 
heterozygous for MCCA-p.R385S (M.R.B. and M.F.D, unpublished data). 
Here, we describe two patients with elevated excretion of 3-MCG and 3-HIVA and with 
partial deficiency of MCC, one of whom has severe neurological symptoms. Both patients 
showed evidence of biotin responsiveness and were heterozygous for MCCA-p.R385S and 
the polymorphic variant MCCA-p.P464H. We provide evidence that MCCA-p.R385S is a 
dominant negative allele leading to biochemical abnormalities and clinical symptoms in 
heterozygous individuals and that it is responsive to pharmacologic doses of biotin in vivo. 
Subjects and Methods 
Case reports 
Patient 1 (MCC047).—This boy was the second child of healthy, nonconsanguineous 
German parents. At the age of 3 wk, he developed infantile spasms. Electroencephalogram 
(EEG) results showed hypsarrhythmia at age 3 mo. Routine cerebrospinal-fluid and brain 
magnetic resonance imaging (MRI) investigations were normal. Therapeutic trials with 
vitamin B6 and vigabatrin did not lead to clinical improvement. At 2 years of age, he 
presented with severe psychomotor retardation, persistent infantile spasms, and 
hypsarrhythmia. MRI of the brain showed significant frontal and parietal cerebral atrophy 
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mainly of the white matter. Metabolic investigations revealed elevated excretion of 3-HIVA 
and 3-MCG without other abnormalities, suggesting MCC deficiency (table 5.1). Biotin 
treatment with 10 mg/d had no clinical or biochemical effect. An increase in the dose to 40 
mg/d (2.7 mg/kg) was associated with dramatic reduction of seizure frequency. Within 4 
wk, the EEG markedly improved, showing the disappearance of hypsarrhythmia, and the 
organic aciduria became virtually normal (table 5.1). On a biotin regimen (50 mg/d) and a 
protein-restricted diet (0.8 g/kg/d, introduced at age 2.5 years), the patient showed no 
further progression of symptoms, and excretion of 3-HIVA and 3-MCG completely 
normalized. Biotinidase activity in plasma was normal. At 7 years of age, he was seizure 
free on a protein-restricted diet (0.8 g/kg/d) and a regimen of vigabatrin and biotin (50 
mg/d), and his EEG was unremarkable. Formal psychometrics were not obtained. 
Patient 2 (MCC048).—This boy was the second child of healthy, nonconsanguineous 
Greek parents. His pre and postpartum history was unremarkable except for a 
hyperbilirubinemia requiring phototherapy. He was referred at age 5 wk because of 
elevated 3-hydroxyisovalerylcarnitine detected by TMS newborn screening. Urinary 
organic acid analysis displayed elevated 3-HIVA and trace amounts of 3-MCG with no 
other abnormalities (table 5.1). To test for a suspected defect in leucine catabolism, the 
patient received an oral leucine load (150 mg/kg). This challenge resulted in transient 
hyperammonemia (up to 134 µmol/L; normal < 80) and in a significant increase in urinary 
excretion of 3-HIVA and 3-MCG (table 5.1) that was partially suppressed by simultaneous 
administration of biotin (5 mg/kg) (table 5.1), suggesting in vivo biotin responsiveness 
similar to that of patient MCC047. Ten other infants who were referred because of elevated 
isovalerylcarnitine detected by TMS were similarly tested but showed normal organic acid 
excretion before and after leucine loading (data not shown). At 18 mo of age, patient 
MCC048 received biotin (5 mg/kg) and carnitine (50 mg/kg) and was developing normally. 
His urinary excretion of 3-HIVA and 3-MCG remained elevated (334 and 11.7 mmol/mol 
creatinine, respectively). Samples from the parents of patient MCC048 were not available. 
Informed consent for this study was obtained from the parents of both patients. 
 65 
 
Cell cultures and carboxylase assays 
Skin fibroblasts were cultured in a standard medium containing 10% fetal calf serum 
(FCS). The biotin concentration of this medium, supplied by the natural biotin content of 
FCS, was 9 nmol/L, or 5-fold the mean normal plasma biotin concentration in humans 
Table 5.1.
 
Effect of Biotin Substitution on 3-HIVA and 3-MCG concentration in Urine
 
 
 
Subject and  
Biotin Substitution  
 
Time after 
Leucine Loada 
(h) 
Concentration in Urine ofb 
(nmol/mol creatinine) 
     
         3-HIVA                      3-MCG 
MCC047:    
   No Biotin --- 276 653 
   10 mg/d for 7 d --- 358 300 
   40 mg/d for 7 d --- 135 44 
   40 mg/d for 3 more wk --- 17 9 
Father of MCC047:    
   No biotin --- 26 ND 
Mother of MCC047:    
   No biotin --- 24 ND 
MCC048    
   No biotin Before load 105 2.2 
   No biotin 0-2 183 12 
   No biotin 2-4 956 33 
   No biotin 4-6 794 35 
   No biotin Before load 100 ND 
   5 mg/kg with leucine at 0 h 0-2 368 6.2 
   No biotin 2-4 471 2.5 
   No biotin 4-6 335 12 
Controls:    
   No biotin --- <18 ND 
aPatient MCC048 was given a leucine load of 150 mg/kg with and without a simultaneous 
biotin load, and urine was collected in three portions after he load. 
bND = not detected. 
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(1.80 ± 0.84 nmol/L, range 0.65 – 4.83 nmol/L; n=126) (Suormala et al. 1997). We 
prepared a biotin-depleted medium by replacing FCS with newborn calf serum (NBCS), 
which resulted in a final biotin concentration of 0.1 nmol/L. To obtain physiological biotin 
concentration, we supplemented the low-biotin medium with 2.0 nmol/L biotin and, to 
obtain a high-biotin medium, with 10 µmol/L biotin (i.e., 5,000 times higher than normal 
plasma levels). The activities of PCC and MCC were assayed in fibroblast homogenates by 
measurement of the incorporation of 14C-bicarbonate into acid-nonvolatile products, by 
methods established elsewhere (Suormala et al. 1985). 
Mutation analysis by RT-PCR and genomic PCR  
We extracted RNA and genomic DNA from skin fibroblast cultures between 5–15 
passages, using RNA and DNA isolation kits from Qiagen. We performed RTPCR using 2–
5 mg of total cellular fibroblast RNA and a cDNA cycle kit (Invitrogen) in accordance with 
the manufacturer’s recommendations. To search for mutations, we used primer pairs in the 
5_- and 3_-UTR to amplify by RT-PCR the complete MCCA or MCCB ORF, as described 
elsewhere (Baumgartner et al. 2001). We used the same approach to amplify the complete 
ORF of the HCS gene. The PCR products were gel purified and were sequenced directly. 
To confirm mutations identified in RT-PCR products, we amplified a genomic fragment 
containing the corresponding exon, using flanking intronic primers, and sequenced the PCR 
product directly (Baumgartner et al. 2001). All PCR reactions (50 ml) contained primers 
(100 ng of each), standard PCR buffer (Gibco-BRL), dNTPs (200 mM), and Taq 
polymerase (2.5 U) (Gibco-BRL). The sequences of all primers are available on request. 
Construction of wild type and mutant MCCA expression vectors 
We cloned the full-length human MCCA (-51 to +2275, where +1 is the A nucleotide of 
the initiation methionine codon) cDNA into a mammalian expression vector (pTracer-
CMV2 [Invitrogen]) at the EcoRI sites, as described elsewhere (Baumgartner et al. 2001). 
To introduce R385S, A289V, L437P, and P464H into MCCA, we harvested an 896-bp 
ACCI fragment from RT-PCR–amplified cDNA from individuals with these variants and 
subcloned the fragment into the wild-type MCCA construct, as described elsewhere 
(Baumgartner et al. 2001). The pTracer-CMV2 vector contains a green fluorescent protein 
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(GFP) gene fused to the Zeocin-resistance gene. We sequenced all constructs in both 
directions to validate the sequences. 
Transfections 
For expression studies, we electroporated the indicated constructs into SV40T-
transformed skin fibroblasts from a patient homozygous for MCCA Q421fs(-1), as 
described elsewhere (Braverman et al. 1997, Baumgartner et al. 2001). These cells have no 
detectable MCCA activity. The cells were harvested after 72 h and were assayed for MCC 
and PCC activities. All transfections were performed in duplicate. Transfection efficiency 
was assessed by scoring a subset of cells in each transfection for the presence of GFP and 
ranged from 10%–20% in these experiments. Transformed fibroblasts from an unaffected 
individual were used as control. 
Allelic Variation in MCCA Expression 
We used the MCCA SNP c.1391C→A, which results in the P464H amino acid change, 
to quantitate allele specific transcripts by means of single-nucleotide primer extension 
(SnuPE) and laser-induced fluorescence capillary electrophoresis, as described elsewhere 
(Mátyás et al. 2002) . This method takes advantage of distinct mobilities of SnuPE products 
with different nucleotides incorporated at their 3’ ends and has been independently shown 
to yield highly quantitative results (Mátyás et al. 2002, Yan and Zhou 2003). 
Results  
Carboxylase activities 
MCC activity in crude homogenates of fibroblasts cultured in standard medium was 
reduced below the normal range in patients MCC047 and MCC048, with an average of 
26% and 36% of the mean control value, respectively (fig. 5.1). This residual activity is 
greater than that in fibroblasts from four typical CRM– MCC-deficient patients (0%–1% of 
mean control value) (fig. 5.1) but is less than that in fibroblasts from six heterozygotes for 
CRM– MCCA or MCCB alleles (72%–118% of control). The activity of another biotin-
dependent carboxylase, PCC, was within the normal range in patients MCC047 and 
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MCC048, indicating that the deficiency of MCC is specific. Moreover, the ratio of MCC to 
PCC activity was consistently below the control range in both patients (MCC047: mean 
0.19, range 0.18–0.19; MCC048: mean 0.24, range 0.19–0.32; 13 controls: mean 0.52, 
range 0.41–0.75). Fibroblast MCC activity levels from the father and the mother of patient 
MCC047 were both at the low end of the normal range (52% and 63% of the mean control 
value, respectively). However, the ratio of MCC to PCC activity was consistently below the 
control range in the father, who was also heterozygous for MCCA-R385S, whereas the ratio 
was normal in three of four experiments in the mother (father of MCC047: mean 0.29, 
range 0.24–0.36; mother of MCC047: mean 0.4, range 0.34–0.42). 
Figure 5.1. MCC and PCC activity in fibroblasts from patient MCC047 and his parents, 
from patient MCC048, from four typical CRM MCC-deficient patients (probands 009, 010, 
012, and 013 in Baumgartner et al. 2001), and from 13 control cell lines grown in standard 
FCS-based medium with a biotin concentration of 9 nmol/L. The indicated activities are the 
mean and range (vertical lines) of four individual experiments each with duplicate 
determinations. Values in the CRM– MCC-deficient patients are the mean and range of 
activities obtained in four different patients. Control values represent the mean and range of 
activities obtained in 13 different cell lines. 
 
To determine whether the extent of the MCC deficiency in our patients’ fibroblasts was 
influenced by the biotin concentration of the medium, we cultured the cells for one passage 
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(17–27 d) in either biotin-depleted (0.1 nmol/L) or high-biotin (10,000 nmol/L) medium 
(table 5.2). After one passage in the biotin-depleted medium, MCC activities in fibroblasts 
from patients MCC047 and MCC048 and from the parents of MCC047 were decreased to 
24%–35% of activity in the high-biotin medium. A similar decrease occurred in control 
cells. 
Even after four passages in the low-biotin medium, MCC activity in the cells from 
patient MCC047 was decreased to only 27% (data not shown). Cells from patients with 
HCS deficiency exhibit a dramatic decrease in MCC activity when cultured in biotin-
depleted medium (Suormala et al. 1997), which makes it unlikely that an abnormality of 
this enzyme contributes to our patients’ biochemical phenotype. Furthermore, MCC and 
PCC activities in cells cultured in medium with a physiological concentration of biotin (2.1 
nmol/L) were similar to those in cells cultured in the high-biotin medium. Increasing the 
biotin concentration to 100 µmol/L in the medium failed to increase the activities of MCC 
further (data not shown). Thus, we found no evidence for an increased biotin requirement 
as the cause of the low MCC activity in the patients’ fibroblasts. Normal kinetics of MCC 
activity were obtained in crude homogenates of fibroblasts from MCC047 when they were 
assayed with varying concentrations of bicarbonate, 3-methylcrotonyl-CoA, ATP, 
magnesium, and chloride in the assay mixture (results not shown). 
These results indicate that a decreased affinity of MCC for these assay components is 
highly unlikely to be the cause of the reduced activity in this patient. Despite these results, 
the ratio of MCC to PCC activity in fibroblasts from patient MCC047, his father, and 
patient MCC048 was reproducibly below the control range, whereas the ratio in fibroblasts 
from the mother of patient MCC047 was within the range of controls (table 5.2). 
Furthermore, MCC and PCC activities in cells cultured in medium with a physiological 
concentration of biotin (2.1 nmol/L) were similar to those in cells cultured in the high-
biotin medium. Increasing the biotin concentration to 100 µmol/L in the medium failed to 
increase the activities of MCC further (data not shown). Thus, we found no evidence for an 
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increased biotin requirement as the cause of the low MCC activity in the patients’ 
fibroblasts.  
 
Normal kinetics of MCC activity were obtained in crude homogenates of fibroblasts 
from MCC047 when they were assayed with varying concentrations of bicarbonate, 3-
methylcrotonyl-CoA, ATP, magnesium and chloride in the assay mixture (results not 
shown). These results indicate that a decreased affinity of MCC for these assay components 
Table 5.2. Activities of 3-MCC and PCC in Fibroblasts Grown in NBCS-Based Low-Biotin Medium (0.1 
nmol/L) and in the Same Medium Supplemented with Phtsiological (2.1 nmol/L) and High (10 µmol/L) 
Biotin Concentration.  
Subject and 
Biotin in Medium 
(nmol/L) 
Carboxylase Activitiesa 
(pmol/min/mg protein) 
MCC PCC MCC/PCC ratio 
MCC047    
.1 31.5 375 .80 
2.1 102 628 .16 
10,000 100 638 .16 
Father of MCC047:    
.1 42.0 280 .15 
2.1 121 446 .27 
10,000 130 498 .26 
Mother of MCC047:    
.1 61.2 315 .20 
2.1 176 500 .35 
10,000 177 472 .38 
MCC048:    
.1 30.4 283 .11 
2.1 120 603 .20 
10,000 128 603 .21 
21 controls, mean ± SD (range):    
.1 145 ± 57 (70.4-292) 494 ± 172 (300-889) .3 ± O.8 (.17-4.3) 
10,000 340 ± 130 (140-606) 694 ± 246 (347-1,246) .5 ± .13 (.29-.85) 
aValues are the mean of duplicate determinations within one experiment. 
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is highly unlikely to be the cause of the reduced activity in this patient. Despite these 
results, the ratio of MCC to PCC activity in fibroblasts from patients MCC047, his father 
and patient MCC048 was reproducibly below the control range, whereas the ratio in 
fibroblasts from the mother of patient MCC047 was within the range of controls (Table 
5.2). 
Mutation analysis  
Despite high residual MCC activity in vitro, the pattern of metabolic abnormalities in 
our patients suggested a partial defect at the level of MCC in vivo. To investigate this 
possibility, we sequenced the entire ORF of MCCA and MCCB in the products of RT-PCR 
amplification of fibroblast RNA in patients MCC047 and MCC048. We found that both 
patients and the father of patient MCC047 are heterozygous for an A→C transversion at 
position 1155, creating a new restriction site for NheI (GCTAGArGCTAGC) and 
substituting a serine for an arginine at position 385 (MCCA-R385S). Patients MCC047 and. 
MCC048 and the mother of MCC047 are heterozygous for the previously described neutral 
polymorphism 1391CrA (MCCA-p.P464H). The father of MCC047 does not carry this 
polymorphism. 
 
 
Figure 5.2. Detection of the MCCA 1155A       C (R385S) mutation in the MCC047 nuclear family. 
The 327-bp fragment amplified from genomic DNA (MCCA exon 11) was subjected to digestion 
with NheI. The wild-type fragment is not cut, whereas the R385S fragment is cleaved into 
fragments of 130 bp and 197 bp. 
 
 
From this, we conclude that the MCCA-R385S allele encodes a proline at codon 464. We 
found no other sequence abnormalities over the entire length of the MCCA and MCCB 
wt bp
327
197
130
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ORFs. We confirmed these results by direct sequencing of PCR-amplified genomic DNA 
followed by digestion with NheI (fig. 5.2). We also amplified and sequenced all MCCA 
exons and flanking intronic sequences in patient MCC047 and found no additional 
mutations. Because biotin responsiveness in other carboxylase-deficient patients has been 
shown to be due to deficiency of HCS, we also RT-PCR amplified and sequenced the entire 
HCS ORF and found no sequence abnormalities 
Expression studies 
In previous experiments, we showed that MCCA-p.R385S and several other MCCA 
missense alleles conferred no MCC activity when transfected into MCCA null cells 
(Baumgartner et al. 2001). To test if MCCA-p.R385S also has a dominant negative 
influence on the activity of MCCA wild type, we cotransfected both alleles into an SV40T-
transformed MCCA-deficient reference cell line and measured MCC activity 72 h later. 
In two separate experiments, cotransfection of MCCA wild-type allele with vector 
without an insert restored MCC activity to 55% of nontransfected control fibroblasts, 
whereas cotransfection of MCCA wild type with MCCA-p.R385S restored MCC activity to 
25% — that is, to ~ 50% of that obtained with wild type coexpressed with vector without 
an insert. In contrast, cotransfection of MCCA wild type with either MCCA-p.A289V or 
MCCA-p.L437P restored MCC activity to the same level as that obtained with wild type 
coexpressed with vector without insert (fig. 5.3). Thus, the reduction of MCC activity is 
specific for MCCA-p.R385S. We repeated the experiment using the MCCA–wild-type 
construct with histidine instead of a proline at codon 464 (MCCA-p.P464H) with similar 
results. Thus, the dominant negative effect of MCCA-p.R385S when coexpressed with the 
wild-type allele is independent of the P464H polymorphism. 
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Figure 5.3. The effect of coexpression of MCCA missense alleles and wild-type MCCA. MCC-
deficient cells were cotransfected with wild type MCCA plus MCCA alleles with the indicated 
missense mutation. Activities represent mean and range obtained in two individual experiments 
MCC activity of cells cotransfected with wild-type MCCA and a vector without an insert was set a 
100%. 
 
 
Allelic variation in expression 
Recent reports have shown variation in expression of apparently wild-type alleles, for as 
many as 50% of all genes (Yan et al. 2002, Lo et al. 2003). This variation in expression 
ranges ≥ 2–4 fold, segregates with the allele, and could markedly affect the consequences 
of heterozygosity for a recessive loss-of-function mutation on the other allele. To determine 
if allele-specific variation in expression was playing a role in the manifestation of MCC 
deficiency in individuals heterozygous for MCCA-p.R385S, we used a fluorescent dideoxy-
terminator–based method to distinguish the mRNA products of individual alleles in patient 
MCC047, his mother, and patient MCC048, by use of the MCCA-p.P464H polymorphism 
to mark the alleles. In patient MCC047 and his mother, both alleles were expressed at equal 
levels, whereas, in patient MCC048, the expression of the MCCA-S385 allele (marked by 
P464 in cis) was reduced to ~ 40% of that of the wild-type MCCA allele (marked by H464) 
(fig. 5.4). Thus, in these heterozygous individuals, we found no evidence for significant 
variation in expression of the MCCA wild-type allele. 
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Figure 5.4. Allelic variation in MCCA expression. A sample of electrospherograms of SnuPE 
products from the sense strand of RT-PCR-amplified DNA from patient MCC047 and his mother 
and from patient MCC048. Mobility of tetramethyl-6-carboxyrhodamine (TAMRA)-labelled allele-
specific SnuPE is shown for the MCCA polymorphic variant c.1391C        A (MCCA-P464H). Each 
peack represents a specific allelic variant. Allele 1 with an A nucleotide at c.1391 encodes 464H, 
whereas allele 2 with a C nucleotide at c.1391 encodes 464P and the functionally significant 385S. 
The relative quantification of each allele represents the mean and range of two independent 
experiments performed on fibroblasts RNA.  
 
Discussion 
Both patients described here showed a persistent characteristic organic aciduria, with 
elevated excretion of 3-MCG and 3-HIVA suggesting MCC deficiency. One suffered from 
severe neurological symptoms starting at the age of 3 wk, whereas the other was an 
asymptomatic newborn detected by TMS newborn screening. In patient MCC047, excretion 
of the disease-specific metabolite 3-MCG was within the range found in patients with 
severe MCC deficiency (Sweetman and Williams 2001); in patient MCC048, urinary 3-
MCG was lower but was persistently elevated. Enzymatic determination of MCC activity in 
cultured fibroblasts revealed a partial but specific MCC deficiency. In both patients, 
residual fibroblast MCC activity was not abnormally sensitive to biotin depletion, nor was 
it enhanced by addition of high concentrations of biotin to the medium. These results rule 
out HCS deficiency as the cause of reduced MCC activity and are consistent with the 
clinical features and the persistent organic aciduria in our patients. 
MCC048
Allele 1 = 61% (59-63)
Allele 2 = 39% (37-41)
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C
MCC047
Allele 1 = 48% (46-50)
Allele 2 = 52% (50-54)
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 75 
Our mutation analysis of the MCCA and MCCB genes revealed that both patients are 
heterozygous for a previously described missense mutation, MCCA-p.R385S, and a known 
polymorphism, MCCA-p.P464H (Obata et al. 2001). In earlier studies, we showed that 
MCCA-p.R385S confers no MCC activity when transfected into reference MCCα-deficient 
cells (Baumgartner et al. 2001). We found the MCCA-p.R385S allele in 1 of 132 control 
chromosomes from white individuals (Baumgartner et al. 2001). 
An arginine at position 385 (or the corresponding position) is strictly conserved in 
mammalian, plant, fungal, and bacterial carboxylases (Samols et al. 1988, Jitrapakdee and 
Wallace 1999), and the corresponding residue in the biotin carboxylase domain of 
Escherichia coli acetyl-CoA carboxylase (R338) has been shown to be part of a positively 
charged pocket for bicarbonate binding (Thoden et al. 2000). 
To explain the biochemical abnormalities in both patients and the clinical phenotype in 
patient MCC047, we hypothesize a dominant negative influence of the mutant S385 MCCA 
subunit on MCC activity. A dominant negative effect of the protein product of a mutant 
allele usually involves homomeric or heteromeric proteins. 
Typically, the protein product of a dominant negative allele is functionally inactive and 
has the added property of inhibiting the activity of the protein product of the normal allele 
(Herskowitz 1987). To achieve this, the dominant negative mutant protein product must be 
stable and must be able to assemble into the normal multimeric protein complex. 
MCCα S385 fulfills these criteria. In contrast to the protein products of all other MCCA 
missense alleles, the MCCα S385 protein is stable (Baumgartner et al. 2001, Gallardo et al. 
2001). On protein-blot analysis using avidin alkaline phosphatase as a probe, MCCα S385 
accumulates to levels equal to or greater than normal (Baumgartner et al. 2001). Despite 
this, expression studies clearly show that the MCCα S385 is catalytically inactive 
(Baumgartner et al. 2001, Desviat et al. 2003). Moreover, the results of our cotransfection 
experiments show that expression of MCCα S385 but not of two other MCCA missense 
alleles inhibits the function of coexpressed wild-type MCCα protein. Taken together, these 
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data strongly support our hypothesis of a dominant negative effect of MCCα S385 on the 
wild-type protein and thus on MCC activity. 
Additional evidence comes from the recent studies of Sloane and Waldrop (2004), who 
used the purified homodimer of the biotin carboxylation subunit of E. coli acetyl CoA 
carboxylase to study kinetic properties of mutant proteins. They showed that E. coli biotin 
carboxylase-R338S, the missense mutant corresponding to MCCA-p.R385S, exhibited a 
dominant negative effect on the function of the wild-type active site, by negative 
cooperativity with respect to bicarbonate concentration (Sloane and Waldrop 2004). 
Furthermore, they presented evidence that the degree of negative cooperativity is decreased 
with increasing concentrations of biotin. These data support our hypothesis of a dominant 
negative effect of MCCα S385 on the wild-type protein and thus on MCC activity. 
The presence of a functionally significant mutation in the second allele would also 
explain the reduced MCC activity in our patients. However, we searched extensively for a 
functional mutation on the second allele by RT-PCR of mRNA of the entire MCCA ORF, 
as well as by amplification and sequencing of all MCCA exons and flanking intronic splice 
sites from genomic DNA. By direct sequencing of the RT-PCR product, we could clearly 
see that both patients are heterozygous for the R385S change, which indicates that the 
second allele produced a stable mRNA transcript, but we found no molecular abnormalities 
in the MCCA transcript or structural gene that could explain a reduction in the function of 
its protein product. For all of these reasons, we concluded that MCCα S385 has a dominant 
negative effect on the wild-type protein. 
How do we explain the lack of biochemical abnormalities in other R385S heterozygotes 
(e.g., the father of MCC047)? The MCCA-p.R385S heterozygotes with normal urinary 
organic acids who we have studied were all adults. Thus, one possible explanation is that 
the metabolic demands on the pathway are lesser in adults than in infants and children. This 
would also be consistent with the identification of asymptomatic adults with severe MCC 
deficiency (Gibson et al. 1998, Baumgartner et al. 2001). An alternative and nonexclusive 
explanation for the phenotypic variation in MCCA-p.R385S heterozygotes has to do with 
the amount of functional MCCα produced from the wild-type allele. Recent studies have 
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suggested that alleles of as many as half of all genes examined exhibit ≥2–4 fold allelic 
variation in expression and that this characteristic segregates with the alleles from one 
generation to the next (Yan et al. 2002, Lo et al. 2003). If this is the case for MCCA, then 
the expression level of the wild-type allele would be an additional variable affecting the 
consequences of heterozygosity for a nonfunctional allele. A heterozygote with a low-
expression wild-type allele might be clinically and/or biochemically symptomatic. 
Conversely, a heterozygote with a high-expression wild type allele would be normal. 
However, our allelic expression studies showed approximately equal expression of both 
alleles in patient MCC047 and his mother. In patient MCC048, we found slightly reduced 
expression of the MCCA-R385S allele (marked by P464) as compared with the wild-type 
allele (fig. 5.4). This result may explain the less severe biochemical abnormalities and 
clinical phenotype in this patient. 
Additional factors that could influence the phenotypic consequences of MCC deficiency 
include the extent to which the pathway is stressed by dietary or other environmental 
factors (e.g., excessive protein breakdown associated with an intercurrent infection). In this 
regard, the father of patient MCC047 is described as being healthy during infancy and 
childhood. Finally, normal variation in genes whose protein products have the potential to 
modify the function of MCC or the demands on the pathway could also influence the 
phenotype of MCC deficiency. MCCB and HCS are obvious candidate modifier genes for 
MCCA, but we found no sequence variation in either of these genes in our patients.  
It is surprising that the clinical symptoms in patient MCC047 and the biochemical 
phenotype in both patients appeared to respond to high doses of biotin. A biotin-responsive 
form of MCC deficiency has not been reported elsewhere (Sweetman and Williams 2001), 
even in Germany, where MCCA-p.R385S appears to be a common allele. In part, this may 
be because of failure to administer high doses of biotin on the order of 2–5 mg/kg/d. Biotin 
responsiveness in our patients is consistent with the observation that MCCA-p.R385S 
produces a stable protein and that other cofactor-responsive disorders are allele specific 
(e.g., cystathione b-synthase) (Mudd et al. 2001). It also agrees with the findings of Sloane 
and Waldrop (2004), who showed that biotin decreases the negative cooperativity of E. coli 
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biotin carboxylase with a missense mutation in the residue corresponding to MCCA-
p.R385S. Alternatively, a biotin dependent increase in the level of MCCA mRNA also 
could explain biotin responsiveness. A regulatory role for biotin in the control of HCS and 
carboxylase mRNA levels through a signalling pathway that requires HCS, guanylate 
cyclase, and cGMP-dependent protein kinase has recently been proposed (Solorzano-
Vargas et al. 2002).  
To provide further evidence for biotin responsiveness in our patients, additional clinical, 
biochemical, and molecular studies in patients with biotin versus without biotin would be 
useful. This was not possible, however, because of parental unwillingness (for patient 
MCC047) and ethical considerations regarding the asymptomatic patient MCC048. For the 
future, we recommend careful documentation of the consequences of biotin administration 
in newly diagnosed patients, especially those carrying the MCCA-p.R385S allele. 
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6. Genotype-Phenotype Correlation 
During our study, a number of asymptomatic but affected siblings were detected in some 
of the families, indicating a disease penetrance consistently lower than 100%. In general, 
the genotype-phenotype correlation in MCC deficiency is loose, with great variability in 
both genotype and clinical severity, even among family members carrying the same 
mutations. Thus other, still unknown, genetic or epigenetic/environmental factors must play 
an important role in the phenotypic expression of MCC deficiency. This can include 
polymorphic variants or silent mutations of the MCCA or MCCB gene itself, which may 
contribute to the variability in the phenotypic expression. 
Combining this study with other previously reported studies, three MCCA and six 
MCCB mutant alleles occurred in 2 or more subjects. The majority of the MCC-deficient 
patients, however, carry private mutations, i.e. no prevalent mutant allele has been detected 
for either gene.  
In the MCCA gene, the missense mutation MCCA-p.R385S, discussed in chapters 4 and 
5, is the most common so far, with a total of 11 mutant alleles detected in 9 subjects 
(Baumgartner et al. 2001, Baumgartner et al. 2004, Dantas et al. 2005, Gallardo et al. 2001, 
this thesis). From these 9 subjects two were homozygous for the mutation, one with a 
severe phenotype and the other asymptomatic, both of German origin (Baumgartner et al. 
2001, Steen et al. 1999, this thesis). One subject was compound heterozygous with mild 
symptoms  (Gallardo et al. 2001). Two further subjects were heterozygous for the mutation, 
one with severe phenotype and the other asymptomatic (Baumgartner et al. 2004), and five 
were compound heterozygous and have remained asymptomatic (Baumgartner et al. 2001, 
Dantas et al. 2005). Only time will tell if these subjects will remain asymptomatic. The 
MCCA-p.Q421AfsX10 (c.1263_1264insG) mutant allele occurred in a total of 3 alleles in 
two subjects with mild symptoms, an American homozygote and a Swedish compound 
heterozygote (Baumgartner et al. 2001, Dantas et al. 2005). MCCA-p.T693TfsX1 
(c.2079_2080delA) was identified in the homozygous state in a Turkish child with mild 
symptoms (not published), and in an asymptomatic compound heterozygous child of 
unknown origin (Holzinger et al. 2001).  
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With regard to the MCCB gene, the missense allele MCCB-p.E99Q has been detected in 
the homozygous state in a Turkish child with fatal outcome and in an adult 
Amish/Mennonite with mild symptoms (Bannwart et al. 1992, Baumgartner et al. 2001). 
However, in this study we also identified this missense allele in a further homozygous and a 
compound heterozygous asymptomatic subject (Dantas et al. 2005). MCCB-p.R155Q was 
identified in the homozygous state in a Turkish asymptomatic newborn, but also in a 
compound heterozygous Vietnamese child with mild symptoms (Baumgartner et al. 2001, 
Beemer et al. 1982, Dantas et al. 2005). MCCB-p.V339M was detected in two compound 
heterozygous Turkish subjects, both with severe symptoms (Baumgartner et al. 2001, 
Wiesmann et al. 1998). The missense allele MCCB-p.P310R was detected in the compound 
heterozygous state in a Vietnamese and in the homozygous state in a Australian child, both 
with mild clinical symptoms (Baumgartner et al.2001, Beemer et al.1982, Dantas et al. 
2005).   
 At position 173 in the MCCB gene we identified the insertion c.517dupT (MCCB-
p.S173FfsX75) followed by a premature stop codon thus causing a truncated β-subunit. 
This insertion was detected in a mildly symptomatic compound heterozygous Swiss patient 
(Baumgartner et al. 2001, Dantas et al. 2005, Gitzelman et al. 1987), an asymptomatic 
compound heterozygous American newborn (Dantas et al. 2005), and two asymptomatic 
homozygous Amish/Mennonite mothers (Baumgartner et al. 2001, Gallardo et al. 2001, 
Gibson et al. 1998). Finally, the mutant allele MCCB-p.F497_V562>GfsX4, a splice 
mutation that skips exon 16, was detected in a homozygous Arabian infant with fatal 
outcome and in an asymptomatic compound heterozygous Turkish newborn (Baykal et al. 
2005, Dantas et al. 2005).  
 Based on still small numbers of subjects, this study did not reveal any obvious 
correlation between genotype and phenotype. No mutations were exclusively present in 
symptomatic or asymptomatic subjects. So far, the three MCCA and six MCCB mutant 
alleles that occurred in two or more subjects appear not to be predictors of a particular 
phenotype. Even though some patients with a severe phenotype are the product of a 
consanguineous union and could have an additional genetic disorder, our data strongly 
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support the idea that factors other than the genotype at the MCC loci have a major influence 
on the phenotype of MCC deficiency. 
While genotypes are stable over the life of an individual, phenotypes are usually unstable 
and reactive (Schulze and McMahon 2004). In the Genomic Glossary web page the term 
phenotype is defined as “The observable structure and functional characteristics of an 
organism determined by its genotype and modulated by its environment” or even “The 
observed manifestation of a genotype, which may be expressed physically, biochemically 
or physiologically” (http://www.genomicglossaries.com/content/genomics_glossary.asp). 
The definition of a term seems to be an easier task than the definition of a phenotype itself, 
and the definition of a phenotype for a genetic study remains a major task for clinical 
research.  
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7. Summary 
3-Methylcrotonyl-CoA carboxylase (MCC) deficiency is a rare disorder of leucine 
catabolism inherited as an autosomal recessive trait. The phenotypic expression of the 
disease is highly variable, ranging from neonatal onset with severe neurological 
involvement to asymptomatic adults. Most patients however are asymptomatic until an 
episode of acute metabolic decompensation following intercurrent illness leads to the 
diagnosis. The metabolic phenotype of MCC deficiency includes a characteristic organic 
aciduria with greatly increased excretion of 3-hydroxyisovaleric acid and 3-
methylcrotonylglycine and elevated blood levels of 3-hydroxyisovalerylcarnitine, usually in 
combination with severe secondary carnitine deficiency due to urinary loss of carnitine 
esters. Introduction of tandem mass spectrometry (TMS) to newborn screening has revealed 
an unexpectedly high incidence of MCC deficiency and indicates that this disorder is the 
most frequent organic aciduria. The Metabolic Unit from the University Children’s 
Hospital in Basel has a well-characterized collection of fibroblast cell lines from patients 
with isolated MCC deficiency, and includes 75 patients from 70 families from several 
different nationalities and ethnic backgrounds. This study addresses molecular 
characterization of MCC deficiency and functional consequences of some of the mutant 
alleles, and thus provides insight into the cellular and molecular biology of MCC and the 
molecular pathology of MCC deficiency.  
7.1. Molecular characterization of MCC-deficient patients by identification of new 
MCCA and MCCB mutant alleles. 
Following the identification of the human cDNAs encoding MCCA and MCCB by three 
independent groups in 2001 (Baumgartner et al. 2001, Gallardo et al. 2001, Holzinger et al. 
2001), this study is focused on the molecular characterization of 70 unrelated MCC-
deficient patients.  
Before the introduction of TMS based newborn screening patients came to attention due 
to clinical symptoms associated with typical organic aciduria. Cultured fibroblasts of such 
patients were sent to Basel for enzymatic confirmation of suspected MCC deficiency. From 
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70 patients 32 presented with clinical symptoms whereas 34 patients were asymptomatic 
newborns detected by TMS based newborn screening, and 4 were affected but 
asymptomatic mothers diagnosed after detection of abnormal metabolites in the neonatal 
screening samples of their healthy babies.  
This study shows mutation analysis in 30 patients, 10 of whom came to attention 
because of clinical symptoms. Another 18 patients were asymptomatic newborns detected 
by TMS based newborn screening, and 2 were asymptomatic but affected mothers. We 
identified 10 MCCA and 14 MCCB novel mutant alleles. Including earlier studies, we have 
characterized a total of 15 MCCA and 23 MCCB mutant alleles in our study population 
(Baumgartner et al. 2001, Dantas et al. 2005). None of the missense alleles were detected in 
a control population of at least 50 individuals indicating that each of these mutant alleles 
has a very low frequency in this control population (Baumgartner et al. 2001, Dantas et al. 
2005). Another 3 MCCA and 3 MCCB mutations have been described by others (Desviat et 
al. 2003, Gallardo et al. 2001, Holzinger et al, 2001). 
7.2. Consequences of MCCA and MCCB missense mutations on MCC activity and 
analysis of steady-state levels of mutant MCCα  protein. 
In order to confirm the pathogenic effect of MCCA and MCCB missense mutations we 
expressed 1 MCCA and 3 MCCB missense alleles using transient transfection of SV40T-
transformed MCCA and MCCB deficient skin fibroblasts (Dantas et al. 2005, this thesis). 
The three expressed MCCB missense alleles showed no or very low residual activity, while 
the MCCA missense allele had 26% residual activity of wild type level, thus confirming 
that these changes have a deleterious effect on enzyme activity. 
To analyze the MCC polypeptides under steady-state condition in fibroblasts of MCCA 
deficient patients, we carried out Western blot analysis. Results demonstrate that the MCCα 
protein was absent in 5 patients homozygous or compound heterozygous for nonsense or 
frameshift mutations that are expected to result in a truncated protein. The MCCα protein 
was also absent in 2 further compound heterozygous patients in whom only one mutant 
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allele could be identified in the RT-PCR products. The second allele could not be detected 
because presumably this mutant allele is unstable and degraded by the mechanisms of 
NMD. In contrast, western blot analysis of the MCCα protein was normal in amount and 
size in 4 patients carrying MCCA-p.R385S. This is in agreement with previous studies 
which show that the protein product of this allele is stable.  
7.3. Investigation of molecular defects with dominant-negative effect on MCC 
activity.  
In fibroblasts from two patients (MCC047 and MCC048) with suspected MCC 
deficiency, activity determination revealed only partial MCC deficiency (20 and 21% of the 
mean control values, respectively). In both patients, residual MCC activity in fibroblasts 
was not abnormally sensitive to biotin depletion nor was it enhanced by addition of high 
concentrations of biotin to the culture medium (Baumgartner et al. 2004). Mutation analysis 
of the MCCA and MCCB genes revealed that both patients are heterozygous for MCCA-
p.R385S, and a known polymorphism MCCA-p.P464H (Obata et al. 2001). Despite an 
extensive search for a functional mutation on the second allele by RT-PCR and sequencing 
the entire MCCA and MCCB ORF, as well as by amplification and sequencing of all MCCA 
exons and flanking intronic sequences from genomic DNA, no other coding alterations 
were identified. 
MCCA-p.R385S fulfills all the criteria of a dominant-negative allele. In contrast to the 
protein products of other MCCA missense alleles, the MCCα R385S protein is stable 
(Baumgartner et al. 2001, Gallardo et at. 2001, this study). Results of co-transfection 
experiments show that expression of MCCα S385 but not two other MCCA missense alleles 
reduce the activity of co-expressed wild type MCCα protein (Baumgartner et al. 2004).  
Our data strongly support the hypothesis of a dominant-negative effect of MCCαS385 on 
the wild-type protein and thus on MCC activity. Biotin can partially reverse this dominant 
negative effect thus resulting in biotin responsiveness in vivo. This is the first example of 
biotin responsiveness for an isolated deficiency of any of the biotin-dependent 
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carboxylases, suggesting that therapeutic trials with biotin in patients carrying this mutant 
allele are warranted. 
7.4. Genotype-Phenotype Correlation. 
Molecular genetic analysis of MCC-deficient patients provided new information on the 
nature of mutations in the MCCA and MCCB genes and allowed the comparison of 
mutations in symptomatic patients and asymptomatic subjects detected by newborn 
screening (Baumgartner et al. 2001, Dantas et al. 2005, this thesis). Combining our present 
data with our previous results (Baumgartner et al 2001) we have now complete mutation 
analysis in 50 out of 70 probands with confirmed MCC deficiency. 22 out of 50 were 
detected by newborn screening. Regarding the question of whether different mutations 
occur in symptomatic versus asymptomatic subjects we did not identify mutations that are 
specific for either group. Our results provide strong evidence that factors other than the 
genotype at the MCC loci, such as modifying genes and environmental factors, have a 
major influence on the phenotypic expression of MCC deficiency.  
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8. Outlook  
In conclusion, our studies provide insight into the molecular pathology of MCC 
deficiency. Furthermore, this work increases the understanding of the variables that 
influence the phenotypic consequences of MCC deficiency. This will eventually lead to 
guidelines for treatment which are needed for the increasing number of identified subjects 
due to the recent introduction of tandem mass spectrometry in newborn screening 
programs. Finally, this work on MCC will serve as a paradigm for the understanding of the 
molecular mechanism of other biotin-dependent carboxylases and of the pathophysiology in 
such disease states. 
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